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ABSTRACT 
The pathology of Alzheimer’s disease (AD) is characterised by the misfolding and 
aggregation of amyloid-β (Aβ) into extracellular plaques and aggregation of tau into 
intracellular neurofibrillary tangles. Recent advances in molecular imaging have allowed the 
development of positron emission tomography (PET) tracers for the in vivo detection of Aβ 
plaques while current efforts focus on the evaluation of recently proposed tracers targeting 
tau pathology. This thesis is composed of three main parts. Part one compares two Aβ PET 
tracers ([11C]PIB and [18F]florbetapir) when administered to different but matched patient 
cohorts, and explores the effect of age on the distribution of Aβ-positive PET scans. Part two 
focuses on the first in vivo evaluation of the tau-specific tracer [18F]THK5317, using a 
longitudinal multi-modal design, in a sample of cognitively normal volunteers, patients at 
different clinical stages of AD and individual patients with atypical parkinsonism. The third 
part describes the direct in vivo comparison of the binding properties of two tau-specific 
tracers ([11C]THK5351 and [11C]PBB3) when injected into the same patients with AD on the 
same day. The results indicated that, firstly, the binding of the Aβ-specific PET tracers, 
[11C]PIB and [18F]florbetapir, was highly comparable in individuals from different cohorts. 
Furthermore, age plays an important role in the distribution of Aβ-positive PET scans, with 
the oldest old patients with cognitive complaints appearing to benefit substantially from 
clinical assessment with Aβ PET. Secondly, the tracer [18F]THK5317 detected the expected 
load and regional distribution of tau pathology in vivo in a sample of patients with AD and 
patients with atypical parkinsonism. The distribution of [18F]THK5317 binding differed from 
that of Aβ deposition in patients with AD, although regional correlations existed, indicating 
areas where Aβ and tau pathologies were co-located. The regional load of tau pathology 
([18F]THK5317) was associated with measures of global cognition and episodic memory, 
with local hypometabolism playing a mediating role in this relationship. Longitudinally, a 
heterogeneous pattern of changes was observed in the binding of the tau tracer [18F]THK5317 
in patients with AD, in contrast to the homogeneous changes in glucose metabolism that 
better tracked cognitive deterioration. The build-up of tau pathology ([18F]THK5317) and the 
development of local hypometabolism appeared temporally dissociated, with a stronger 
relationship detected between the two when hypometabolism changes became more 
prevalent, in the later stages of the disease. Finally, different tau-specific tracers 
([11C]THK5351 and [11C]PBB3) seemed to bind in vivo to different molecular targets; 
[11C]PBB3 binding appeared to correlate closer to Aβ deposition, while [11C]THK5351 
binding followed the expected regional pattern of tau pathology in AD and related closer to 
downstream markers of the disease. Further investigation of the existing PET tracers and 
development of new tracers is required for shedding light on the pathological processes that 
contribute to neurodegeneration in AD and for developing clinical markers that allow early 
and highly accurate discrimination between different proteinopathies.  
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1 INTRODUCTION 
 
1.1 FROM NORMAL AGEING TO DEMENTIA 
 
1.1.1 Ageing 
Age-related progressive decline in intrinsic physiological functioning, associated with 
increased morbidity and mortality, is a common definition of ageing. 1,2 In the brain, normal 
ageing is linked with various structural and functional changes that are associated with a 
gradual decline in specific cognitive functions (e.g. processing speed, memory, etc.), which 
do not interfere with the activities of daily living. 3 However, the links between normal 
cognitive ageing and the age-related neurodegenerative diseases that lead to substantial 
cognitive deficits and functional disability remain elusive. 
 
1.1.2 Dementia 
Dementia can be described as the acquired loss of cognitive function, severe enough to 
interfere with daily life, caused by brain disease or injury. 4 According to the Diagnostic and 
Statistical Manual of Mental Disorders, 5th edition, the diagnosis of major neurocognitive 
disorder (previously dementia) diagnosis is mainly based on evidence of significant cognitive 
decline from a previous level of performance in one or more cognitive domains (complex 
attention, executive function, learning and memory, language, perceptual-motor, or social 
cognition), with these cognitive deficits interfering with independence in everyday activities. 
The diagnosis is made after the exclusion of other mental disorders that could explain the 
cognitive deficits (e.g. major depressive disorder, schizophrenia). 5 
According to the Centers for Disease Control and Prevention USA, dementia is the sixth 
leading cause of death, behind heart disease, cancer, chronic lower respiratory diseases, 
accidents and stroke. More specifically, one in three seniors die with dementia, and 46 
million people are estimated to live with dementia worldwide. 6 In Sweden it is estimated that 
more than 160,000 people suffer from dementia at the moment, 7 a prevalence comparable to 
that in other European countries. It is worth mentioning that, as age is the strongest known 
risk factor for dementia, the prevalence of dementia is expected to nearly double every 20 
years, due to the global increase in population size and life expectancy, according to the 
World Alzheimer Report. 8 Dementia is not only associated with disability and mortality but 
also with dependence and societal costs, which place a great burden on families, communities 
and societies, especially since dementia is a terminal condition and the patients live for many 
years after the onset of symptoms. 9 It is noteworthy that the total worldwide cost of dementia 
in 2015 was US$ 818 billion and is set to reach US$ 2 trillion annually by 2030. 8 The annual 
cost of dementia in Sweden is calculated to exceed the SEK 60 billion in total, or SEK 
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398,000 per person with dementia per year. 10 A growing body of evidence illustrates the 
dramatic increase in global prevalence and societal costs of the ‘dementia epidemic’ 11 and 
highlights the need for prioritising dementia in the public health research agenda 
internationally. 
 
1.1.2.1 The spectrum of dementia 
The set of symptoms grouped under the general term dementia do not refer to a single 
clinico-pathological entity, but rather to several diseases with distinct characteristics, 
although a substantial clinical and pathological overlap between them has been observed. 
Alzheimer’s disease (AD) is the most common neurodegenerative disorder and cause of 
dementia, accounting for 50-70% of all dementia cases. 12 Other causes of dementia include 
frontotemporal lobar degeneration, vascular dementia, Lewy body disease, etc. (Figure 1). It 
should be noted that dementias with mixed underlying pathologies are a common finding; 
these show increased prevalence with increasing age. 13 Finally, other diseases have been 
linked to dementia (e.g. Down’s syndrome, traumatic brain injury, Parkinson’s disease, 
Huntington's disease, Creutzfeldt-Jakob disease) or dementia-like syndromes that may be 
reversed with the appropriate treatment (e.g. delirium, pseudodementia, infections, etc.). 
 
Figure 1. Pie chart illustrating the distribution (percentage, %) of diagnoses following memory assessment of 
more than 500 patients at the memory clinic, Karolinska University Hospital, Sweden, over one year (data from 
2015). The coloured slices show the frequency of a diagnosis of dementia syndrome (34% in total). DLB = 
dementia with Lewy bodies; FTLD = frontotemporal lobar degeneration; Mixed = mixed dementia; NOS = 
dementia not otherwise specified; RCD = reversible cognitive disorder due to other medical conditions; VaD = 
vascular dementia. 
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1.1.3 Mild cognitive impairment 
Mild cognitive impairment (MCI) is a clinical diagnosis with heterogeneous underlying 
causes that is thought to represent an intermediate stage between normal ageing and the 
diagnosis of dementia. 14 The diagnosis is assigned in the presence of objective cognitive 
decline in one or more cognitive domains that is not expected for the age and education of the 
patient, and normal activities of daily living in the absence of a dementia disorder. 
Subsequent revisions of the diagnostic criteria have classified patients with MCI into four 
categories based on the impairment of memory and/or other cognitive domains; 15 
predominant impairment of memory has been more closely associated with later progression 
to AD. 16,17 The diagnosis of MCI represents a risk factor for a subsequent dementia 
diagnosis, 18 although not all patients will eventually develop dementia; a substantial number 
of patients will remain stable or even reverse to normal cognition over time. 19,20 
 
1.1.4 Subjective cognitive decline 
A substantial percentage of patients presenting with cognitive complaints are discharged with 
a clinical diagnosis of subjective cognitive decline (SCD) (Figure 1). The diagnosis is made 
in the presence of a self-perceived decline in cognitive performance, not related to an acute 
event, and normal performance on standardised cognitive tests, adjusted for individual age 
and educational attainment. 21,22 Individuals with SCD represent an etiologically 
heterogeneous group with a subset of individuals developing objective cognitive deficits in 
the future. Although observations suggest that SCD is a risk factor for future development of 
MCI or dementia, 23-26 the relationship over time between subjective and objective cognitive 
decline remains unclear and has attracted great interest from the scientific community. 
 
1.2 ALZHEIMER’S DISEASE 
In 1984, McKhann, et al. 27 in a working group established by the National Institute of 
Neurological and Communicative Disorders and Stroke and the Alzheimer Disease and 
Related Disorders Association (now Alzheimer’s Association), defined AD as ‘a brain 
disorder characterised by progressive dementia that occurs in middle or late life’. The 
pathological characteristics of the disease include the presence of neurodegeneration, neuritic 
plaques and neurofibrillary tangles (NFTs), as discussed below. Clinically, the disease 
usually manifests after the sixth decade of life, typically starting with impairment of short-
term memory early in the disease course, before the development of more extensive cognitive 
deficits. However, the clinical presentation of the disease can be heterogeneous, with 
different clinical phenotypes described, 28-30 and substantial overlap could exist in the clinical 
symptomatology of AD and other dementia syndromes. 31 
According to the most widely accepted diagnostic criteria, 16 a diagnosis of AD can be made 
clinically in the presence of a progressive dementia disorder with two confidence levels 
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(namely, possible and probable). A probable diagnosis is made in the presence of dementia 
with deficits in at least two cognitive domains, progressive cognitive decline, no disturbance 
of consciousness, and onset of the disease after 40 years of age and after the exclusion of 
other systemic or brain diseases; a possible diagnosis is made with an atypical clinical 
presentation or in the presence of other significant diseases. Finally, a definite diagnosis of 
AD can only be assigned in the presence of histopathological evidence of the disease in 
autopsy or biopsy specimens. 32 The level of uncertainty described in the clinical criteria for 
AD reflects the only moderate agreement between the clinical and neuropathological 
diagnoses, 33 as well as the absence, until very recently, of reliable laboratory or in vivo 
imaging markers of the underlying pathology. 
While the cause of AD remains elusive, a number of risk factors have been identified. 
Specifically, increasing age, carriage of the apolipoprotein E ε4 (ApoE4) allele, family 
history and low educational attainment are associated with increased prevalence of sporadic 
AD. 34-36 A number of modifiable cardiovascular risk factors have been associated with 
increased risk of AD, including the presence of diabetes, obesity, smoking, hypertension, 
hypercholesterolaemia, and the lack of physical activity. 37 
 
Figure 2. Illustration of the main pathological features of AD. Extracellular deposits of Aβ fibrils together with 
other proteins form the Aβ plaques, while intracellular deposits of tau filaments form the neurofibrillary tangles 
in AD. Inflammatory cells (i.e. reactive astrocytes and activated microglia) surround the Aβ plaques. 
  5 
1.2.1 Neuropathology 
Alois Alzheimer in 1906 was the first to identify and describe the neuropathological 
characteristics of a ‘peculiar severe disease process of the cerebral cortex’ later named after 
him, as Alzheimer’s disease. The characteristics of AD in the first patient to be described 
consisted of the presence of miliary foci of silver-staining deposits (later known as neuritic 
plaques), and bundles of fibrils (later known as NFTs), along with atrophy in the brain. 38  
 
1.2.1.1 Amyloid-β plaques 
Amyloid-β (Aβ) plaques are extracellular fibrillar deposits of insoluble Aβ protein (Figure 2). 
39,40 Aβ protein is formed by the cleavage, by β- and γ-secretases, of the parent molecule, the 
amyloid precursor protein (APP; gene located on chromosome 21), an integral membrane 
protein. 41,42 Aβ is released extracellularly, and under normal conditions is mainly cleared into 
the cerebrospinal fluid (CSF) and later removed by the blood. 43 An imbalance between Aβ 
production and clearance in AD is thought to lead to the abnormal accumulation of the 
protein. 44 Aβ monomers aggregate into oligomers and these, based on the conformation they 
adopt, can be categorised into fibrillar-insoluble (β-
sheet structure) or prefibrillar-soluble forms. 45 The 
insoluble forms are further aggregated into longer 
Aβ40 or Aβ42 β-sheet fibrils (Figure 3). Of note, Aβ42 
is considered the most toxic species of Aβ. The Aβ 
fibrils together with other deposited proteins (e.g. 
ApoE, interleukins, complement, etc.) form the 
extracellular Aβ plaques. 46 Two types of plaque 
have been described, based on their morphology; 
diffuse and dense-cored plaques. 47 Neuritic plaques 
are a specific subtype of dense-cored plaques that 
consist of Aβ deposits surrounded by dystrophic 
neurites rich in deposits of abnormally 
hyperphosphorylated tau protein. 48 
The evolution of the regional distribution of Aβ 
plaques during the course of AD has been described 
in detail; the neocortex is the first to be involved 
(Phase 1), followed by the hippocampus and 
entorhinal cortex (Phase 2), the basal ganglia (Phase 
3), the brainstem (Phase 4) and finally, the 
cerebellum (Phase 5). 49,50 The development of Aβ 
plaques is thought to start affecting the cortex in 4% 
of all neuropathology cases in the fourth decade, 
with Aβ pathology estimated to become prevalent in 
Figure 3. The 3D structure of an Aβ42 fibril 
obtained by using hydrogen-bonding 
constraints in quenched hydrogen/deuterium-
exchange nuclear magnetic resonance. The 
fibril consists of two stacked, parallel β-
sheets. Adapted with permission from Luhrs, 
T. et al. 3D structure of Alzheimer's amyloid-
beta(1-42) fibrils. Proceedings of the National 
Academy of Sciences of the United States of 
America 102, 17342-17347, (2005). 
Copyright 2005 National Academy of 
Sciences. 
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more than 50% of all individuals in the eighth decade of life. 51 Given the fact that a diagnosis 
of AD is typically made after the sixth decade and that the incidence rate of clinical AD, even 
in the eighth decade, does not exceed the 5%, 52 it is apparent there is a long preclinical phase 
of Aβ accumulation and that a large number of individuals carry a substantial amount of Aβ 
pathology without ever developing the disease. 
 
1.2.1.2 Tau pathology 
The bundles of fibrils (NFT) that Alois Alzheimer described were in fact intraneuronal 
aggregates of the abnormally hyperphosphorylated microtubule-associated protein tau 
(MAPT) (Figure 2). 53 Tau protein, a cytoskeletal component that is abundant in the neuronal 
axons, plays an important role in regulating neuronal growth and axonal transport and 
stabilising the structure of the microtubules, a function that is regulated by the normal 
phosphorylation of tau. 54,55 More specifically, the dephosphorylated tau binds to the 
microtubules and promotes their polymerisation, while its phosphorylation causes tau to 
dissociate from the microtubules. Tau is encoded in the MAPT gene in chromosome 17, and 
alternative mRNA splicing of the gene leads to six possible tau isoforms, three with three and 
three with four microtubule-binding domain repeats (i.e. 3R and 4R, respectively). 56 While in 
the foetus the predominant form of tau is the 3R form, which binds less stably to 
microtubules, in the healthy adult brain the 3R and 4R isoforms are equally expressed. 57 
Although tau is most abundant in neurons, astrocytes and oligodendroglia also contain tau, 
although this is essentially the 4R tau isoform. 
58,59 Both 3R and 4R tau undergo pathological 
hyperphosphorylation in AD, in contrast to 
other less common neurodegenerative diseases 
involving accumulation of tau protein (aka 
tauopathies), where there is predominant 
involvement of either 3R or 4R tau. 60 The 
hyperphosphorylation is followed by the 
aggregation of tau into β-sheet paired helical 
filaments (Figure 4), which form the insoluble 
NFTs intracellularly. 53 Although, under normal 
conditions, tau is located mainly in the axons of 
the neurons, the aggregation of tau leads to its 
redistribution to the soma and dendrites of the 
affected neurites. 61 Three stages of aggregation 
of NFTs have been described, namely the pre-
tangles (non-filamentous soluble aggregates), 
the intracellular mature tangles (condensed 
fibrillar deposits) and the extracellular ghost 
tangles (which arise after the death of the 
Figure 4. The 3D structure of the tau protofilament 
core obtained by cryo-electron microscopy. (A) 
Sequence alignment of the four microtubule-binding 
repeats (R1–R4) with the observed eight β-strand 
regions coloured from blue to red. (B) Rendered 
view of the secondary structure elements in three 
successive rungs. Adapted with permission from 
Macmillan Publishers Ltd: Nature, Fitzpatrick, A. 
W. P. et al. Cryo-EM structures of tau filaments 
from Alzheimer's disease. Nature 547, 185-190, 
(2017). Copyright 2017. 
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neuron containing the mature tangles, named 
‘tombstone’ lesions). 62,63 Recent evidence 
suggests that there are differences in the tau 
isoform profile in the different stages of NFT 
deposits. A profile shift is observed from the 
predominantly 4R tau deposits in the non-
fibrillar pre-tangles to predominantly 3R tau in 
the ghost tangles, while equal expression of 
isoforms is reported in the mature NFT. 64 Based 
on autopsy studies tau pathology, but not Αβ 
accumulation, has been closely associated with 
both neuronal loss and cognitive impairment in 
patients with AD, and it is thought to be a marker 
of progression of AD. 65-68 However, although 
tau aggregation could lead, according to the 
current hypothesis, to cell death due to disruption 
of microtubule stability and axonal transport, the 
underlying mechanism is poorly understood. 55,69-
71 To add to this uncertainty, there is 
experimental evidence suggesting that neurons 
can tolerate a substantial amount of tau 
pathology for longer intervals than expected, 
raising the possibility that NFT formation could 
even act protectively against neuronal loss. 72-74 
The regional distribution of NFTs in AD evolves 
in a predictable manner over time starting from the transentorhinal cortex and progressively 
affecting the hippocampus, the adjacent inferior temporal lobe, the cortical association areas 
and finally the primary cerebral cortices. 49,75 It should be noted that the exact area of initial 
NFT deposition remains controversial, since it is thought that the tau pathology could be 
detected in the brain stem, and more specifically in the locus coeruleus, before it affects the 
transentorhinal cortex. 76 Most autopsy studies published to date have highlighted the 
importance of the localisation of the NFT deposits, especially in relation to the cognitive 
performance of the individual affected. 77 While NFT pathology in the medial temporal lobe 
is considered to be asymptomatic, in other words to be an inevitable process of ageing, 51 
spreading of the pathology to the adjacent neocortex has been associated with cognitive 
impairment, while severe dementia is thought to occur when the whole neocortex is affected. 
78 The stereotypical propagation of tau pathology has led researchers to suggest that the 
pathology could spread in a prion-like manner. According to this hypothesis, the formation of 
misfolded tau aggregates in affected neurons could be transmitted to other neurons where the 
aggregates act as templates for the seeded aggregation of the native tau in the ‘healthy’ 
neuron. There is evidence of this from experimental studies in animal models and this 
represents a promising area for future research (for a detailed review, see 79-81). 
Figure 5. Illustration of the temporal spreading of 
(A) Αβ plaques and (B) NFTs in the AD brain. 
AC = allocortex; BFB = basal forebrain; BN = 
brainstem nuclei; CB = cerebellum; ENT = 
entorhinal cortex; LC = locus coeruleus; NC = 
neocortex; TH = thalamus. Adapted with 
permission from Macmillan Publishers Ltd: 
Nature reviews. Neuroscience, Brettschneider, J., 
Del Tredici, K., Lee, V. M. & Trojanowski, J. Q. 
Spreading of pathology in neurodegenerative 
diseases: a focus on human studies. Nature 
reviews. Neuroscience 16, 109-120, (2015). 
Copyright 2015.  
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Although both Aβ plaques and NFTs follow stereotypical spatial spreading in the AD brain, 
the propagation profiles of the two pathologies are substantially different, as demonstrated in 
Figure 5. A long preclinical phase of NFT aggregation has been proposed, based on post-
mortem studies; 82,83 data from these studies suggest that the formation of NFTs could even 
precede Aβ plaque deposition in the course of AD. 84-87 
 
1.2.1.3 Neurodegeneration 
The AD brain is characterised by macroscopic atrophy with decreased brain weight and 
enlargement of the ventricles. 88 Microscopically, the neurodegeneration is expressed by 
neuronal loss and reduced synaptic density in both allo- and neo-cortical areas, which 
correlates closely with the cognitive function of the patient (Figure 2). 89-92 More specifically, 
changes in synaptic integrity are observed, with degeneration of the axons and subsequent 
neuronal death. 93,94 
 
1.2.1.4 Neuroinflammation 
Neuroinflammation in AD is not limited to the presence of interleukins and component 
proteins in association with Aβ plaques. 95 Autopsy studies have revealed the existence of 
both activated microglia and reactive astrocytes proximal to Aβ plaques (Figure 2). 96-98 
Microglial cells are inflammatory cells that can be primed (multiplied and activated) in 
response to their microenvironment. Activated microglia are characterised by pro-
inflammatory and anti-inflammatory states, and are partly involved in the phagocytic 
clearance of Αβ. 99 Reactive astrocytes have diverse phenotypes, 100 and although they have 
been associated with the clearance of Aβ 101 their role seems more complex. Specifically, it 
has been suggested that reactive astrocytes could play an additional role in both Αβ 
accumulation and the induction of oxidative stress. 102-104 
 
1.2.1.5 Neuropathological criteria 
Despite intense efforts to develop biomarkers that will detect in vivo changes in the AD brain, 
post-mortem neuropathological evaluation remains the gold standard in the diagnosis of AD. 
The recently described neuropathological criteria 32,105 for an AD diagnosis are based on a 
combination of the assessments of the phases of Aβ plaques development, 50 the stages of 
NFT spreading 49,106 and a semi-quantitative assessment of the neuritic plaque load. 107 
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1.2.2 Amyloid cascade hypothesis 
The amyloid cascade hypothesis, formulated in 1992 by Hardy and Higgins 108, is still the 
most widely accepted conceptualisation of the pathogenesis of AD. The factors that led to 
formulation of the hypothesis include the identification of mutations in the APP gene 
(chromosome 21) as deterministic for the development of autosomal dominant AD, 109,110 and 
the very high prevalence of the disease in patients with Down’s syndrome (trisomy 21). 
40,111,112 According to this hypothesis, Aβ plays a central role in the neuropathology of the 
disease, with its accumulation leading to the abnormal hyperphosphorylation of tau protein 
and neurodegeneration. However, through the years, a number of weaknesses have tested the 
validity of this hypothesis. 113 For example, Aβ deposition is common in cognitively normal 
elderly; 114 then the animal models with overexpression of the APP gene do not develop 
substantial neurodegeneration or the AD phenotype of cognitive impairment; 115,116 Aβ 
accumulation does not show a close relationship with cognitive impairment, especially at the 
symptomatic stages of the disease; 65 and anti-Aβ drugs have, so far, failed to change the 
course of the disease, at least in its later stages. 117-119 
Refinement of the amyloid hypothesis 120,121 and alternative models of AD pathogenesis has 
been proposed in order to account for the weaknesses of the hypothesis formulated by Hardy 
and Higgins 108. Aβ-soluble oligomers are thought, now, as the most neurotoxic form of Aβ 
aggregates that could drive tau pathology, although our knowledge about their role remains 
fragmentary. 122-126 According to this hypothesis, the fibrillar Aβ plaques may not be harmful 
but will instead act as ‘inert sinks’ for the accumulation of Aβ oligomers.  
Alternative models, where tau pathology or neuroinflammation are of central interest, have 
also been proposed, 84,121,127-129 although these have received less attention to date. 
 
1.2.3 Cognitive performance 
The term neuropsychological assessment is used to describe the administration of a number 
of tests for evaluation of the cognitive function and functional status of an individual. The 
assessment typically evaluates the performance in different cognitive domains (i.e. memory, 
perception, attention, language, visuospatial ability and executive function) and it is being 
used extensively in the clinical examination of patients with cognitive symptoms. On an 
individual level neuropsychological test results can be compared to age/education matched 
normative data (or z-scores from a population mean) and similarly results can be compared 
statistically on a group level e.g. age/education matched cognitively normal individuals 
compared to patient groups. Both individual and group level comparisons allow 
neuropsychologists to determine whether cognitive impairment is present in that 
person/group. The selective impairment of episodic memory is thought to be an early sign of 
AD, and has been associated with neurodegeneration in the medial temporal lobe, particularly 
the hippocampus. 130 Furthermore, the progression of the pathology in the neocortex is 
associated with additional impairment in other cognitive domains. 131 Overall, although 
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neuropsychological testing is very sensitive to the detection of cognitive deficits in relation to 
the cognitive background of the individual, 132 it is not highly accurate alone in the 
differential diagnosis of the underlying pathology. 133 
 
1.3 CORTICOBASAL DEGENERATION AND PROGRESSIVE 
SUPRANUCLEAR PALSY 
Corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP) are two 
neuropathological entities characterised by the aggregation of abnormally 
hyperphosphorylated tau protein; tau aggregates are localised in neurons (i.e. neurofibrillary 
tangles), astrocytes (i.e. tufted astrocytes for PSP 
and astrocytic plaques for CBD), as well as 
oligodendrocytes (i.e. coiled bodies). 134 In contrast 
to AD, in CBD and PSP 4R tau is predominantly 
involved, and straight tau filaments are formed. 
The involvement of basal ganglia is common to 
both PSP and CBD, while the involvement of other 
cortical and subcortical areas differs between the 
two; for example PSP commonly affects the 
brainstem and the dentate nucleus of the 
cerebellum while CBD affects several grey- and 
white-matter brain areas asymmetrically, with a 
greater load of pathology contralateral to the 
affected side. 60,135,136 Clinically both diseases are 
associated with the presence of atypical 
parkinsonism, executive cognitive deficits and 
other symptoms, including postural instability, 
ophthalmoparesis or progressive apraxia, 
depending on the regional distribution of the 
underlying pathology. 137-139 The clinical 
syndromes associated with PSP and CBD (PSP 
and corticobasal syndromes, respectively), 
however, could be difficult to distinguish, since the 
diseases show a substantial clinical and 
neuropathological overlap (Figure 6). 140-144 
Moreover, these syndromes have also been 
associated with neuropathological evidence of AD 
or with the presence of tau-negative inclusions, 
which further complicates the reliable clinical 
diagnosis in those patients. 145,146  
Figure 6. Atypical parkinsonian syndromes 
(right panel) and associated 
neuropathological findings (left panel). The 
weight of the strings in the diagram 
illustrates the approximate strength of the 
clinicopathological correlations. CBS = 
corticobasal syndrome; Pick’s = Pick’s 
disease; PSPS = progressive supranuclear 
palsy syndrome. Figure inspired by Miller, 
B. L. & Boeve, B. F. The behavioral 
neurology of dementia. 2nd edition, 
Cambridge University Press, (2016) and 
Rohrer, J. D. & Rosen, H. J. Neuroimaging 
in frontotemporal dementia. International 
review of psychiatry 25, 221-229, (2013). 
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1.4 BIOMARKERS 
‘Biomarker: A characteristic that is objectively measured and 
evaluated as an indicator of normal biological processes, pathogenic 
processes, or pharmacologic responses to a therapeutic intervention’ 
as defined by the Biomarkers Definitions Working Group. 147 
A number of biomarkers have recently been employed to help in the differentiation of 
neurodegenerative diseases and causes of dementia, aiming for early detection and staging of 
the pathology, and are also being used to monitor the therapeutic efficacy of disease-
modifying drugs. 148 Investigation into the clinical validity of two of these, molecular imaging 
and CSF markers, has progressed furthest relative to other biomarkers. 
 
1.5 MOLECULAR IMAGING 
Advanced neuroimaging techniques have allowed imaging of structural and functional 
biological abnormalities in vivo. Computed tomography, magnetic resonance imaging (MRI) 
and positron emission tomography (PET) are only some of the developed imaging 
technologies; each modality presents with different advantages and limitations. While 
computed tomography and structural MRI were developed for imaging the structure of 
systems clinically, PET allows the imaging and quantification of biochemical processes in 
vivo by incorporating positron-emitting isotopes into molecular radiotracers. 149 
 
1.6 MAGNETIC RESONANCE IMAGING 
Structural imaging of the brain with MRI offers highly sensitive detection in vivo of brain 
abnormalities such as atrophy, trauma, tumours, vascular changes (i.e. stroke, bleeding, etc.), 
mass lesions and other intracranial findings. MRI does not use ionising radiation but instead 
uses combination of magnetic fields, radio waves, and field gradients to image the anatomy 
of the brain with a wide range of contrasts. Several studies in the field of neurodegeneration 
have highlighted differences in terms of atrophy between cognitively normal individuals and 
patients with cognitive impairment, and have also shown that it is possible to discriminate 
between the different underlying causes of neurodegeneration and dementia, based on 
specific atrophy patterns. 150,151 More specifically, in AD atrophy changes have been typically 
observed in temporo-parietal areas, including the medial temporal lobe, 152 although atrophy 
variants have also been observed in patients with AD. 153 The extent of atrophy has been 
associated with post-mortem evidence of neuronal loss, with the underlying NFT pathology 
as well as with cognitive decline and is considered a very good marker of disease 
progression. 154-157 Visual scales of medial temporal atrophy 158 have been part of the 
diagnostic assessment in specialised memory units with good accuracy in discriminating 
between patients with dementia from cognitively normal volunteers, although it has proven 
less useful in differentiating between different causes of dementia. The use of automatic 
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procedures for measuring patterns of atrophy might lead to wider use of MRI imaging in the 
differential diagnosis of the different causes of cognitive impairment. 159 
Several MRI sequences have been developed in recent years to allow the imaging of different 
physiological processes, which widens the application of MRI in the field of 
neurodegeneration. These include imaging of cerebral blood flow with arterial spin labelling, 
imaging cerebral connectivity using diffusion weighted imaging sequences, measuring 
cerebral activation with functional MRI, and detecting levels of metabolites using 
spectroscopy sequences. 160-163 However, clinical validation of these techniques is still 
pending. 
 
1.7 POSITRON EMISSION TOMOGRAPHY 
The introduction of PET imaging allowed in vivo detection of the load and regional 
distribution of different molecular targets, based on the binding of specially designed tracers. 
The first human PET scanner was documented in 1976 at Washington University, St. Louis, 
USA, by Phelps, et al. 164 PET is based on the detection of a pair of 511 keV annihilation 
gamma-rays, which are produced after the β+ decay of a positron-emitting short-lived 
radioactive isotope. Radioactive isotopes are atoms with unstable nuclei that release energy 
when they undergo decay, in order to be transformed in a more stable state. For the purposes 
of PET, isotopes that will undergo positron-emitting decay shortly after production (i.e. that 
have a short half-life; e.g. 11C, 18F, 13N and 
15O) are artificially produced in a particle 
accelerator called a cyclotron. These 
isotopes are incorporated into molecules 
(i.e. the molecules are labelled as tracers), 
which are known to target different 
biochemical processes, to form the 
radiotracer that will be injected into the 
patient. Following the injection, the 
radiotracer is distributed into specific areas 
in the body, based on its pharmacological 
characteristics, where it binds to its 
molecular target. When the isotope decays, 
the atom transforms one of its protons into 
a neutron and emits a positron. The 
positron travels a short distance before it 
‘meets’ its anti-particle, the electron. The 
contact of the two will leads to their 
annihilation or, in other words, the 
transformation of their mass into energy, as 
detected by the production of an anti-
Figure 7. Illustration of the basic principles behind PET 
imaging. Δt = time between the arrival of each of the anti-
parallel pair of photons; c = speed of light; d = distance 
from the detected annihilation to the midpoint of the 
scanner on the line connecting the coincidence events. 
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parallel (180°) pair of photons (gamma-rays; 511 keV each) (Figure 7A). The anti-parallel 
pair of photons is expected to reach detectors at each side of the ring of the PET scanner 
roughly at the same time (Δt < 10 ns). The scanner is able to record these coincidence events 
as deriving from the same annihilation. With the use of more advanced coincidence 
processing, the location of the annihilation can be determined on the line connecting the two 
activated photon detectors (d = c Δt / 2) (Figure 7B). The events recorded are later 
reconstructed as an image using computation algorithms. Detection of the pair of photons 
deriving from the same annihilation is the reason for the higher sensitivity of PET over other 
imaging modalities, even with the injection of very low concentrations of radiotracer. 
However, because of detector physics, PET is characterised by low resolution relatively to 
computed tomography or MRI, and therefore does not provide useful structural information. 
165 
An ideal radiotracer should be able to penetrate the blood–brain barrier adequately without 
being a P-glycoprotein substrate, would have high affinity (binding affinity usually in nM 
range) and selectivity for the target with a low off-target signal, would have favourable 
pharmacokinetics for PET imaging (rapid brain uptake and wash-out), would lack radioactive 
metabolites able to cross the blood–brain barrier and, finally, would be safe for administration 
in low doses. 166 Different isotopes can be used for radiolabelling the tracers, each one with 
different advantages and disadvantages. Isotopes with a very short half-life (e.g. [11C] with a 
20 min half-life) have been very useful in the research setting, allowing multi-tracer PET 
imaging in vivo on the same day; they, however, require an on-site production. In contrast, 
isotopes with a longer half-life (e.g. [18F] with a 109 min half-life) can be produced in a 
cyclotron centrally and the radiolabelled tracers can be delivered to geographically dispersed 
sites, thus allowing the clinical application of the radiotracer even in centres without access to 
highly-specialised facilities and personnel. More than 40 radiolabelled tracers targeting 
specific biological processes have been developed through the years for the study of brain 
diseases. 167 
 
1.7.1 Glucose consumption 
2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG), a radiolabelled glucose analogue, is used as a 
PET tracer to measure metabolic glucose consumption within a targeted tissue. FDG is 
transported inside the cell, mediated by glucose transport proteins and is phosphorylated by 
hexokinase. However, unlike normal glucose, FDG cannot enter the glycolytic pathway and 
is trapped inside the cell, allowing the rate of trapping, and thus metabolic rates of glucose 
consumption to be approximated with dynamic PET imaging. Its use in neuroimaging, and 
dementia research, has been longstanding. A reduced [18F]FDG signal is associated with 
neurodegenerative changes including neuronal dysfunction, changes in synaptic activity and 
neuronal death. 168-175 Recent evidence, however, is challenging the idea that the [18F]FDG 
signal reflects neuronal activity exclusively, since activated astrocytes may also contribute to 
the observed signal. 176 However, the contribution of each cell type remains elusive. 
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The uptake of [18F]FDG is lower in patients with AD than in cognitively normal individuals, 
especially in the temporo-parietal association cortices, the precuneus and the posterior 
cingulate gyrus, also called the FDG signature regions for AD (Figure 8). 177,178 [18F]FDG 
uptake declines over time in patients with AD, in these cortical regions; 179 the change in 
uptake is closely correlated to cognitive decline in the patients. 180 Moreover, the exact spatial 
patterns of low uptake of [18F]FDG tend to reflect the different clinicopathological variants of 
AD, 181-183 as well as to differentiate with high specificity between AD and other causes of 
dementia, including the different types of frontotemporal lobar degeneration or Lewy body 
disease. 184 Changes in uptake of [18F]FDG have been observed even earlier than the onset of 
dementia, in patients with MCI, 185 although the pattern of changes appears heterogeneous, 
probably because of the different causes of MCI. At the MCI stage, [18F]FDG has moderate-
to-high sensitivity and specificity for discriminating between patients who could later develop 
clinical AD and those who could develop other types of dementia. 150,186 The clinical validity 
of [18F]FDG in the differential diagnosis of patients with cognitive complaints has been well 
established, 187 with [18F]FDG PET currently being used in specialised memory units, 
typically as a second-line test where there is diagnostic uncertainty. 
 
1.7.2 Fibrillar amyloid-β deposition 
The identification of a fibrillar Aβ-specific tracer with favourable pharmacokinetics 
([11C]Pittsburgh compound B, [11C]PIB) led to the first in vivo study in human published in 
2004 (Figure 9A). 188 The PIB radiotracer was based on the structure of the fluorescent dye 
thioflavin T, which is widely used to detect beta-sheet structures, including Aβ fibrils and 
NFTs, in autopsied brain tissue or in vitro cultures. [11C]PIB has high affinity for Aβ fibrils 
189 and, injected in vivo, was adequately taken up and quickly washed out from the brains of 
the first study participants. 188 Patients with clinically probable AD have high binding of the 
tracer across the whole neocortex, with the medial temporal cortex relatively spared, in 
comparison with cognitively normal individuals (Figure 9B). Autopsy studies performed in 
patients who had undergone [11C]PIB PET imaging ante-mortem have illustrated the selective 
Figure 8. [18F]FDG PET scan in a patient with a clinical diagnosis of probable AD, illustrating the areas typically 
affected in terms of glucose metabolism. The temporal (TL) and parietal (PL) lobes, including the precuneus 
(PQ), are primarily affected, and the frontal lobe (FL) is also (secondarily) affected. The metabolism of the 
occipital lobe (OL) remains relatively spared. The pons was used as the reference region for the quantification of 
[18F]FDG uptake. 
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binding of [11C]PIB in insoluble fibrillar Aβ deposits (predominantly dense-cored over 
diffuse plaques), including vascular Αβ pathology (i.e. cerebral amyloid angiopathy), and the 
strong correlation between in vivo [11C]PIB binding and region-matched histopathological 
measures of Aβ pathology. Interestingly, in the cerebellum, a region commonly used as a 
reference for quantifying [11C]PIB binding, diffuse Aβ plaques were not labelled with PIB. 
Moreover, PIB did not show evidence of binding to soluble forms of Aβ or to the NFTs. 
179,190-192 
The short half-life of [11C] (~20 min), however, precludes its use in centres without on-site 
radiochemistry facilities, as previously discussed. This led to the development of [18F] Aβ 
PET tracers with longer half-lives (~110 min), which enabled them to be produced centrally 
and be transferred to geographically dispersed sites, thus enabling their widespread use for 
research and in the clinic. Derivatives of PIB were used for the [18F] Aβ PET tracers as can be 
seen by their chemical structures (Figure 9A). All the [18F] tracers were highly comparable 
Figure 9. (A) Illustration of the chemical structures of Aβ-specific PET tracers. PIB and AZD2184 were labelled 
with [11C] while flutemetamol, florbetapir and florbetaben were labelled with [18F]. (B) Cortical projection of 
Aβ-positive and Aβ-negative PET scans. The scans were performed with [11C]PIB in a cognitively normal 
individual (Aβ-negative; left panel) and a patient with a clinical diagnosis of probable AD (Aβ-positive; right 
panel). Cerebellar grey-matter was used as the reference region for quantifying [11C]PIB binding. 
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with [11C]PIB when examined in a head-to-head design, although they showed more 
extensive off-target binding. 193-195 However, the comparability of [11C]PIB and the [18F] Aβ 
tracers when investigated in separate patient cohorts remained largely unexplored. 
Available in vivo evidence with the different tracers shows that in cognitively normal 
individuals the prevalence of Aβ-positivity (Aβ PET binding above the cut-off for positivity) 
increases in an age-related manner, 114 in agreement with previously published 
neuropathological studies, 51 with >30% of individuals over the age of 80 exhibiting 
pathological levels of fibrillar Aβ (measured by Aβ PET). 196 The presence of the ApoE4 
allele is associated with up to three times higher prevalence of Aβ-positivity in cognitively 
normal individuals. 196 The build-up of Aβ deposition, as imaged with PET, is a slow process 
that is thought to start at the preclinical, presymptomatic stage of AD; it can take more than a 
decade before the tracer binding exceeds the threshold of Aβ pathology. The models based on 
longitudinal PET imaging also suggest that the pathology continues to build up for at least 
another decade before it reaches a plateau in patients with AD dementia. 179,197,198 
Interestingly, patients with Aβ-negative MCI will not develop clinically probable AD – with 
a reported sensitivity of 96% – while patients with an Aβ-positive scan will be at high risk of 
the disease (specificity of 72%). 199-201 However, many patients with Aβ-positive MCI will 
not develop probable AD based on different longitudinal studies, which probably reflects the 
relatively short follow-up intervals as well as confirming the neuropathological evidence 
suggesting that a substantial number of elderly possess AD pathology but do not clinically 
manifest AD during their life span. 51 
The introduction of [18F] Aβ PET tracers allowed the validity of Aβ PET to be evaluated 
easily before its clinical incorporation. Furthermore, large validation studies with the different 
tracers have indicated that in vivo Aβ PET imaging is able to accurately show Aβ pathology 
that was later confirmed post-mortem – with a sensitivity and specificity that reached or 
exceeded 90% – further supporting the utility of PET imaging as a biomarker of Aβ 
deposition in the differential diagnosis of syndromes associated with cognitive impairment. 
202-206 Following the evidence from the validation studies, the US Food and Drug Agency and 
the European Medicines Agency recently approved three Aβ tracers ([18F]florbetapir, 
[18F]flutemetamol, [18F]florbetaben) for excluding the presence of Aβ pathology in the 
clinical investigation of cognitive impairment. Since then, appropriate criteria for the clinical 
use of Aβ PET have been published, 207 although the impact of other patient characteristics 
(e.g. age or ApoE4 carrier status) on the utility of this biomarker remains unclear. On-going 
large multi-centre studies are investigating the clinical validity of Aβ PET imaging in greater 
detail in Europe (Amyloid imaging to prevent Alzheimer’s disease; AMYPAD) and the USA 
(Imaging Dementia – Evidence for Amyloid Scanning; IDEAS). Both these studies, and 
others, aim to evaluate the performance of Aβ PET in the management of patients with 
cognitive impairment and the cost-effectiveness of this imaging modality in a clinical setting. 
148 
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1.7.3 Tau pathology 
The wide spectrum of degenerative tauopathies 208 and the close relationship between tau 
pathology, neurodegeneration and cognitive measures in AD, as reported by autopsy studies, 
65,66 raised interest in the development of PET radiotracers that would allow in vivo imaging 
of tau. The addition of tau PET to the imaging arsenal would allow more light to be shed on 
the pathological events that lead to neurodegeneration, the differentiation of tauopathies, and 
the development of new disease-modifying therapies. Everything started with the 
development of [18F]FDDNP in 1999, a tracer that was originally designed to target Aβ 
pathology but that showed additional affinity for tau deposits. 209-211 However, the 
development of tau-specific PET tracers had been particularly challenging (Figure 10) 208,212 
and it would take 10 more years before promising new tracers started to emerge. Tau is a very 
heterogeneous target since it exists in multiple isoforms, as discussed above, undergoes 
different post-translational modifications (i.e. phosphorylation, ubiquitination, truncation, 
etc.), 213 and forms different types of filaments and deposits depending on the underlying 
tauopathies (Table 1). 134,208,214,215 The localisation of tau deposits also varies, as deposits are 
found in neurons and glial cells, in grey and white-matter, and in areas commonly used as 
reference regions in PET (i.e. brainstem and cerebellum). Furthermore, tau deposits are 
characterised by complex dynamic changes over time with distinct maturation stages. To add 
to the complexity of imaging tau pathology, the deposits are predominantly intracellular, in 
contrast to Aβ pathology, and therefore the tracer will need to pass both the blood-brain 
barrier and the cell membrane to reach the target. Furthermore, the common co-localisation of 
tau and Aβ deposits (i.e. neuritic plaques), with relative abundance of Aβ deposits in AD, 
could further complicate evaluation of the specificity of a potential tau tracer. Finally, since 
‘normal’ tau is practically invisible even with immuhistochemistry techniques, 216 the 
detection of ‘abnormal’ insoluble tau could be based on the adopted β-sheet conformations. 
However, caution is advised if this principle is applied to the design of a PET tracer, since the 
β-sheet formation is not specific to ‘abnormal’ tau but is the characteristic structure that is 
adopted by different misfolded proteins (‘amyloids’), associated with neurodegeneration (e.g. 
TAR DNA-binding protein 43 (TDP-43), α-synuclein or Aβ), and this could limit the 
Figure 10. Illustration of the challenges related to the development of tau-specific PET tracers. 
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specificity of the tau tracer. 
Tauopathy Isoforms Filaments Histopathological findings Location 
   Neurons Glial cells  
AD 3R ≈ 4R a Paired helical 
>> Straight 
NFTs 
Neuritic plaques 
Neuropil threads 
– Detailed staging by 
Braak and Braak 49, 
Delacourte, et al. 75 
CBD 4R > 3R Straight 
>> Twisted 
NFTs 
Neuropil threads 
Ballooned 
neurons 
Astrocytic 
plaques 
Coiled bodies 
Grey- and white-
matter areas, 
striatum 
PSP 4R > 3R Straight NFTs 
Neuropil threads 
Tufted 
astrocytes 
Coiled bodies 
Subthalamic nuclei, 
striatum, dentate 
nucleus, cortex b 
Pick’s 
disease 
3R > 4R Straight 
>> Twisted 
Pick bodies 
Pick cells 
– Hippocampus, 
striatum, cortex 
a shift to 3R predominance in the extracellular ‘ghost’ tangles; b variable involvement of the cortex 
Several families of tracers have been developed during the past seven years. The most widely 
used tracers are [18F]THK5317 and [18F]THK5351, which were developed at Tohoku 
University, Japan, [18F]AV-1451 (aka T807 or flortaucipir), which was developed by 
Siemens Medical Solution, USA, and sold to Avid Radiopharmaceuticals, USA (Eli Lilly & 
Co, USA), and [11C]PBB3 which was developed by the National Institute of Radiological 
Sciences in Chiba, Japan (Figure 11A). The tracers showed in vitro high binding affinity to 
and specificity for tau deposits. Moreover, the binding patterns of the tracers in adjacent 
sections of AD brain tissue resembled the pattern of immunohistochemistry with tau-specific 
antibodies (e.g. AT8, PHF-1), further supporting the selectivity of the tracers for tau deposits. 
217-222 There is so far scant evidence for specific targets of the different tracers on tau deposits, 
223 and it would not come as a surprise if they bound to different molecular targets on tau 
pathology, given the heterogeneity of tau. Indeed, recent in vitro evidence has indicated that 
the different tracers may bind to different sites in the AD brain and are likely to image 
different aspects of ‘abnormal’ tau deposition in AD or other tauopathies. 224,225 
When the tracers were injected in vivo, they showed adequate brain uptake and rapid 
washout, although a radiolabelled metabolite of [11C]PBB3 that was able to cross the blood-
Table 1. Common tauopathies and related biochemical and neuropathological characteristics of the 
underlying tau pathology. 
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brain barrier and complicate the quantification of tracer binding was reported. 226-228 
Furthermore, the use of reference regions provided adequate accuracy in quantifying the 
tracer binding, although the use of short static acquisitions was reported not to be optimal 
since it could cause uncertainty in the binding measures. 229 The tracers are now starting to be 
used in continually growing groups of patients with AD and other tauopathies as well as in 
cohorts of cognitively normal elderly. The first studies showed preferential binding of the 
tracers in the temporal lobes of patients with AD with a clear discrimination between the 
patients and age-matched cognitively normal elderly (Figure 11B). 220,230-232 Early studies 
claimed that the binding of the tracers could even replicate the staging of the spreading tau 
pathology, 233-235 as defined by neuropathology studies, although only one case study in a 
patient with AD has been published to date, providing evidence of agreement between in vivo 
tracer ([18F]THK5351) binding and post-mortem measures of tau pathology. 236 Evidence 
suggests a relationship between binding of the tau tracers and measures of Aβ load, 
neurodegeneration, and cognitive impairment, although the exact relationship between these 
markers remains largely unexplored (for a detailed review of the current literature please see 
Saint-Aubert, et al. 223). 237-246 To date, there are no published studies investigating the 
longitudinal progression of tau pathology, as assessed by PET imaging, or the relationships 
Figure 11. (A) Chemical structures of and (B) typical binding surface projections from Aβ-positive (based on 
their PET scans) patients with a clinical diagnosis of probable AD scanned with the most widely studied tau-
specific PET tracers. Different patients were scanned with each tau PET tracer. The surface projection for the 
THK family of tracers was performed with [18F]THK5317 PET data. The [18F]AV1451 image derives from the 
ADNI database. Cerebellar grey-matter was used as the reference region for quantifying the binding of all 
tracers. The DVR was based on the Logan reference graphical and wavelet-aided parametric imaging methods 
for [18F]THK5317 and [11C]PBB3, respectively. 
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over time with other biomarkers of the disease, with the 
exception of the study included in this thesis (paper IV). 
In patients with atypical parkinsonism and a clinical 
diagnosis associated with the presence of CBD or PSP 
pathologies, the tau tracers showed binding in brain areas 
expected from post-mortem studies. 220,247-252 Moreover, 
there was agreement between areas with high tracer 
binding and tau pathology in patients who underwent 
autopsy evaluation, further illustrating that these tracers 
could prove useful in non-AD tauopathies. 253-255 
However, the fact that the tracers bind off-target to areas 
relevant for those tauopathies questions their usefulness in 
discrimination. Indeed, a recent study showed that there 
were no differences between patients with clinical PSP 
and cognitively normal participants. 256 Concerns about 
off-target binding of the tracers have been raised not only 
with regard to imaging non-AD tauopathies but also with 
regard to the general validity of the tracers. Several 
potential sources of off-target binding have been 
suggested, 236,257-261 although a thorough assessment, 
including direct comparisons between tracers, is pending. 
Newly developed tau-specific tracers are thought to have 
improved binding properties with lower off-target signal, 
although no in vivo data have been published so far 
(Figure 12). 
 
1.8 CEREBROSPINAL FLUID MARKERS 
The identification and quantification of Aβ in the CSF 262 led to the development of specific 
assays to measure the Aβ42 isoform. The low levels of Aβ42 in the CSF of AD patients are 
thought to reflect the deposition of Aβ42 into plaques in the brains of these patients, and 
therefore its reduced clearance to the CSF. 263,264 Indeed, an inverse relationship between the 
neuropathological Aβ plaque load and CSF Aβ42 measurements has been observed. 265,266 
However, although part of the scientific community treats CSF Aβ42 and Aβ PET as 
equivalent and interchangeable, a significant number of individuals have shown discordant 
profiles for the two markers of Aβ. 267-270 It cannot, therefore, be ruled out that the two 
biomarkers are capturing slightly different components of Aβ pathology. To add to this 
uncertainty, CSF Aβ42 appears not to be a specific biomarker for AD pathology, since CSF 
Aβ42 reductions have also been observed in other diseases (e.g. Creutzfeldt-Jakob disease, 
amyotrophic lateral sclerosis, multiple system atrophy). 271 
Figure 12. Chemical structures of 
newly developed tau-specific tracers 
that are considered to belong to the 
second generation of tracers with 
improved characteristics. 
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The development of CSF assays for measuring total and phosphorylated tau levels followed 
shortly after those for CSF Aβ42. 272,273 Neuropathological studies, however, illustrated that 
the amount of NFTs detected post-mortem correlated only moderately with CSF total tau, 274 
while the relationship with phosphorylated tau levels was more complex. More specifically, it 
appears that levels of NFTs correlate with measures of tau phosphorylated at threonine 231 
275 but not with tau phosphorylated at threonine 181, 276 the most common clinical measure of 
phosphorylated tau. Studies showing correlations of varying strengths between the binding of 
the newly developed tau-specific PET tracers and CSF tau measures have started to emerge, 
although doubts have been expressed that the two markers are reflecting the same component 
of tau pathology. 277-280 
 
1.9 DIAGNOSTIC ASSESSMENT OF COGNITIVE IMPAIRMENT 
Most patients presenting with cognitive complaints will undergo clinical assessment at a 
primary care unit, according to national guidelines. 281 In Sweden, as part of the initial, 
routine assessment, a detailed history is taken from the patient and informant, followed by 
physical, including neurological, examination, evaluation of the patient’s functional capacity 
to perform activities of daily living and evaluation of the patient’s cognitive performance 
with brief tests (e.g. the MMSE and the clock-drawing tests, as measures of global cognitive 
and visuospatial, executive performance, respectively). Finally, the patient undergoes blood 
tests, and structural brain imaging (computed tomography or MRI), for exclusion of other 
causes of neurological symptoms. If there is uncertainty following the basic assessment or 
with cognitive complaints by relatively young patients (under the age of 65 yrs), it is advised 
that the patients are remitted to secondary specialised units for thorough investigation. This 
could include detailed cognitive assessment performed by a trained neuropsychologist, 
speech and language assessment by a qualified speech pathologist, electroencephalography, 
measurements of CSF markers or imaging with different PET tracers (i.e. [18F]FDG PET or 
Aβ PET). The final diagnosis is often based on consensus from a committee composed of 
geriatricians, neurologists, clinical neuropsychologists, and specialist nurses. 
 
1.10 REVISING THE CLASSICAL DIAGNOSTIC CRITERIA 
The development of biomarkers has reconceptualised the diagnosis of AD. In recent years, 
two sets of different criteria for AD have been published that highlighted the use of 
biomarkers to identify AD accurately in vivo, 282-285 even before the onset of dementia, at the 
preclinical/presymptomatic and prodromal (i.e. MCI due to AD) stages of the disease, in 
contrast to the classical understanding that AD can only be diagnosed with certainty 
neuropathologically. Furthermore, these recent AD criteria have suggested that the available 
biomarkers can be categorised into two groups, based on whether they are specific to the 
underlying AD pathology (i.e. pathophysiological markers; Aβ PET and CSF measures for 
Aβ42 and tau) or whether they can track downstream neurodegeneration indicative of the 
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regional spread of AD pathology (i.e. topographical markers; [18F]FDG and atrophy in MRI). 
282 
 
1.11 TIME COURSE OF THE ALZHEIMER’S DISEASE PATHOLOGY 
In the past two decades, a number of researchers have sought to determine the hypothetical 
time courses of the underlying pathological changes in the brains of patients with AD. The 
first hypotheses were based on neuropathological studies and highlighted the presence of AD 
pathology in cognitively normal individuals, thus indicating the preclinical, silent stages of 
the disease. 82,83 The development of biomarkers has enabled the multi-modal and 
longitudinal evaluation in vivo of the different pathological processes in AD, and has 
subsequently led to revised models. These revised models incorporate measures of Aβ 
deposition, measures of cognitive impairment, and inflammatory and other markers of the 
disease. 286-288 (Figure 13) The incorporation of tau PET tracers in longitudinal, multi-modal 
cohorts of patients with AD may shed light on the temporal evolution of tau pathology. 
Figure 13. Tentative time course of the pathological changes during the development of AD based on 
Nordberg, A. Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early 
diagnosis and drug development. Alzheimer's research & therapy 3, 34, (2011). 
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2 AIMS 
 
This thesis aimed with the use of multi-modal PET imaging, to provide new insights on the 
pathological interplay between tau pathology, neurodegeneration and Aβ deposition, which 
underlie the cognitive impairment in AD. The specific aims for each paper were: 
 
In paper I, to compare the binding properties of two Aβ PET tracers ([11C]PIB and 
[18F]florbetapir) in unrelated but matched patient cohorts, and to examine the effect of age on 
the distribution of Aβ-positive scans. 
 
In paper II, to evaluate, in vivo, the tau-specific PET tracer [18F]THK5317 and to explore the 
relationship between binding of this tracer and markers of Aβ deposition ([11C]PIB) and 
glucose metabolism ([18F]FDG), in a sample of cognitively normal volunteers, patients with 
clinical diagnosis of AD (prodromal or dementia), and individual patients with atypical 
parkinsonism. 
 
In paper III, to investigate the regional relationship between in vivo tau pathology (using 
[18F]THK5317 PET) and cognitive deficits in a cohort of patients with clinical diagnosis of 
AD (prodromal or dementia) and to examine the potential role of glucose metabolism 
([18F]FDG) as a mediator in this association. 
 
In paper IV, to evaluate in a longitudinal multi-modal design the temporal spreading of tau 
pathology (using [18F]THK5317 PET) in relation to changes in glucose metabolism 
([18F]FDG) and cognitive performance in patients with clinical diagnosis of AD (prodromal 
or dementia) and individual patients with atypical parkinsonism. 
 
In paper V, to investigate in vivo the binding characteristics of two different tau-specific PET 
tracers (i.e. [11C]THK5351 and [11C]PBB3) when injected into the same patients with clinical 
diagnosis of AD (prodromal or dementia); and to explore the relationship between the tracer 
binding and other markers of the disease. 
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3 PARTICIPANTS AND METHODS  
 
A thorough description of the participants and the methods applied in each study is presented 
in the respective articles/manuscripts. Specific methodological aspects are discussed in this 
section. 
 
3.1 PARTICIPANTS 
Different samples of patients and cognitively normal volunteers were included in the different 
papers. Below is a brief description of the participants in each study. 
 
3.1.1 Paper I 
The participants were derived from two multi-centre cohorts of healthy volunteers, patients 
with MCI and patients with probable AD. The Diagnostic Molecular Imaging (DiMI) 
consortium was a European-funded project that retrospectively collected, Aβ PET imaging 
data from five European centres; the data were analysed centrally with the aim of evaluating 
the utility of Aβ PET. The Alzheimer’s Disease Neuroimaging Initiative (ADNI) is an on-
going USA-based multi-centre study which aims to test whether serial MRI, PET (including 
Aβ PET), other biological markers, and clinical and neuropsychological assessment can be 
combined to measure the progression of MCI and early AD. The data obtained from the 
ADNI have been organised in an online, open-access database for the research community to 
use. The patients with MCI and probable AD in both cohorts fulfilled the classical diagnostic 
criteria. 14,27,289 We used data from 213 DiMI and 916 ADNI participants, which included a 
mixture of healthy volunteers, patients with MCI and patients with probable AD. For the 
comparison with the DiMI cohort, we used an age-, gender-, and MMSE-matched group of 
participants from the ADNI. For the comparison between age groups, we divided the ADNI 
sample into two gender- and MMSE-matched groups, based on an age threshold of 75 yrs (n 
= 363 in each age group). 
 
3.1.2 Papers II-V 
All patients included in papers II-V were recruited from the Memory Clinic at the 
Department of Geriatric Medicine, Karolinska University Hospital, Stockholm, Sweden, after 
thorough clinical investigation including medical history, physical examination, laboratory 
blood tests, ApoE genotyping, neuropsychological assessment, CSF sampling and structural 
imaging. For paper II, 13 patients with MCI, nine with probable AD and two with atypical 
parkinsonian syndromes (one with possible CBD 138 and one with probable PSP 137) were 
recruited. A subgroup of the patients from paper II was included in the analyses for paper III, 
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with a smaller subset of the same sample completing a longitudinal follow-up for paper IV. 
For paper V, a new group of five patients with MCI and four with probable AD were 
recruited. The diagnosis was based on the consensus of a committee, which included 
geriatricians, neurologists, clinical neuropsychologists, and specialist nurses. Although all 
participants were clinically diagnosed according to the classical criteria for MCI and AD, 14,27 
for the purpose of these projects the patients were reclassified based on the new research 
criteria for AD. 282 More specifically, patients with MCI or AD and Aβ PET or CSF (Aβ42 
and tau) evidence of AD brain pathology were classified to prodromal AD or AD dementia 
groups, respectively. According to this classification, for paper I, 11 patients fulfilled the 
criteria for prodromal AD and nine for AD dementia. For paper V, five participants were 
classified in the prodromal AD and four in the AD dementia groups. 
Nine cognitively normal volunteers (five young and four elderly) were also recruited in paper 
II for validation purposes. The inclusion criteria for the cognitively normal volunteers 
included the absence of cognitive complaint, prior head injury, or known 
neurological/psychiatric disorder. They were all non-smokers and free from medication. 
 
3.2 COMPLIANCE WITH ETHICAL AND REGULATORY STANDARDS 
All participants and their caregivers provided written informed consent prior to all 
investigations and all procedures performed were in accordance with the ethical standards of 
the institutional and national research committee and with the 1964 Helsinki Declaration and 
its later amendments, or comparable ethical standards. All studies were approved by the 
Regional Ethical Review Board in Stockholm, Sweden, and the Radiation Safety committees 
at the Karolinska University Hospital in Stockholm and the Uppsala University Hospital in 
Uppsala, Sweden. The study reported in paper V was additionally approved by the Medical 
Products Agency in Sweden since the protocol included the intravenous injection in patients 
with a novel PET tracer ([11C]THK5351). 
 
3.3 NEUROPSYCHOLOGICAL ASSESSMENT 
All the participants described above underwent extensive neuropsychological assessment, at 
their respective clinics for the multi-centre studies (DiMI and ADNI) (paper I) or at the 
Memory Clinic at the Department of Geriatric Medicine, Karolinska University Hospital, 
Stockholm, Sweden, for the studies included in papers II-V. For papers II-V, the participants 
underwent baseline assessment, with the participants of the only longitudinal study (paper IV) 
undergoing additional follow-up neuropsychological evaluation (median interval = 17 
months; interquartile range = 15:18). 
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3.3.1 Paper I 
MMSE was selected as a measure of global cognitive function over other more detailed 
neuropsychological tests because of the wide heterogeneity in the neuropsychological 
batteries used among the different centres (DiMI) or between the different cohorts (DiMI 
versus ADNI).  
 
3.3.2 Paper II-V 
Global cognition and episodic memory tests were selected to characterise the participants in 
papers II-V, and to perform regression analyses against PET imaging measures (papers III-
V). For the regression analyses, the MMSE and the full-scale intelligence quotient (FSIQ), 
which is based on five subtests from the Wechsler adult intelligence scale (Similarities, 
Information, Block Design, Digit Span, and Digit Symbol), 290 were used as measures of 
global cognition. The FSIQ was presented either alone or in relation to the premorbid 
cognitive function of the individual, as assessed with the irregularly spelled words subtest 
from the Swedish National Adult Reading Test. 291 Encoding and delayed recall from the Rey 
auditory verbal learning test, and delayed recall from the Rey-Osterrieth complex figure test 
were used for regression analyses for episodic memory (Table 2). The results of all the 
neuropsychological tests were reported following a z-score transformation for comparison 
with a reference group of age-matched cognitively normal volunteers. 292 
 
3.4 MULTI-MODAL PET DESIGN 
The multi-modal PET design used in all the papers described in this thesis was a powerful 
tool that enabled the detailed in vivo characterisation of different aspects of the AD 
pathophysiology at the same time point. This approach is based on the injection of different 
radiotracers on the same day or in close temporal proximity, to the same participant. Apart 
from the evaluation of different pathophysiological processes, this approach enables the 
unbiased, direct comparison of different radiotracers in the same individual on the same day, 
as described in paper V. Tracers with [11C] labelling were preferred for ‘multi-tracer’ imaging 
Global cognition Episodic memory 
MMSE Rey auditory verbal learning; encoding 
FSIQ Rey auditory verbal learning; delayed recall 
Decline in FSIQ from  
premorbid cognitive function 
Rey-Osterrieth complex figure; delayed recall 
Table 2. Neuropsychological tests used in this thesis for cognitively assessing the participants. 
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on the same day, because of the very short half-life of the isotope, which allows imaging with 
two, or even more radiotracers with an interval of just a few hours between injections. 
 
3.4.1 Image acquisitions 
3.4.1.1 Paper I 
Aβ PET imaging data were available for all participants from the DiMI and ADNI cohorts, 
([11C]PIB and [18F]florbetapir, respectively); [18F]FDG imaging data were available only for 
the ADNI cohort. PET acquisitions were performed on different PET scanners with different 
protocols for every centre within the different cohorts. A 3D T1 MRI sequence was available 
for a subset of 151 participants from the DiMI cohort and all 916 ADNI participants. 
 
3.4.1.2 Papers II-IV 
All patients in papers II-IV underwent, in close temporal proximity, baseline tau, Aβ and 
glucose metabolism PET imaging using [18F]THK5317, [11C]PIB and [18F]FDG, 
respectively. The healthy volunteers underwent only tau ([18F]THK5317) PET imaging, with 
the exception of the elderly who underwent an additional Aβ ([11C]PIB) PET scan to exclude 
the presence of underlying Aβ pathology. All participants underwent a 3D T1 MRI sequence 
at baseline. The patients involved in longitudinal investigations underwent follow-up 
[18F]THK5317 and [18F]FDG PET imaging scans after a median interval of 17 months 
(interquartile range = 15:18) (paper IV). All [18F]THK5317 and [11C]PIB PET acquisitions 
were dynamic (0-60 min) and performed on an ECAT EXACT HR+ scanner (Siemens/CTI) 
or a Discovery ST PET/CT scanner (GE) at the Uppsala PET centre, Uppsala, Sweden. The 
[18F]FDG PET acquisitions were static (30-45 min) and were performed on a Biograph mCT 
PET/CT scanner (Siemens) at the Department of Nuclear Medicine, Karolinska University 
Hospital Huddinge, Stockholm, Sweden. 
 
3.4.1.3 Paper V 
All patients in paper V underwent imaging with the tau-specific PET tracers [11C]THK5351 
and [11C]PBB3 on the same day, as well as with the Aβ PET tracer [11C]AZD2184 within a 
week. All PET acquisitions were dynamic (0-90 min for [11C]THK5351 and 0-60 min for 
[11C]PBB3 and [11C]AZD2184) and were performed on a high-resolution research tomograph 
(HRRT, Siemens/CTI) at the Centre for Psychiatry Research, Karolinska Institutet, 
Stockholm, Sweden. A 3D T1 MRI sequence was also acquired for all patients, within three 
months from the PET investigations. 
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3.4.2 Test-retest evaluation 
As part of the investigations for paper II, five patients (four with prodromal AD and one with 
possible CBD) underwent a second PET scan with [18F]THK5317 within one month of the 
first investigation. This aimed to evaluate, for the first time, the test-retest variability of the 
tracer. 
 
3.4.3 Image pre-processing 
3.4.3.1 Paper I 
The [11C]PIB and [18F]florbetapir imaging data were non-linearly spatially normalised to 
population-specific PET templates in the Montreal Neurological Institute (MNI) space for 
both tracers (SPM5), where the tracer binding was quantified. The [18F]florbetapir template 
was based on the procedure previously applied to the [11C]PIB data. 201,293 Briefly, 207 
[18F]florbetapir images were co-registered to their respective T1 MRI sequences, and were 
later normalised to MNI space using the non-linear transformation matrix from the individual 
T1 MRI sequence segmentations. An average [18F]florbetapir image was subsequently 
created and used as a template for the spatial normalisation of all [18F]florbetapir imaging 
data to MNI space. 
 
3.4.3.2 Papers II-IV 
The individual [18F]THK5317, [11C]PIB and [18F]FDG imaging data were co-registered to the 
individual native T1 MRI sequences (SPM8), where the binding/uptake of the tracers was 
quantified. 
 
3.4.3.3 Paper V 
A different approach was selected for preserving the high-resolution of the PET imaging data 
in paper V. The T1 MRI sequences of the individual patients were co-registered to the 
individual [11C]THK5351, [11C]PBB3 and [11C]AZD2184 imaging space (SPM12). The 
tracer binding was quantified in the native PET space, which was different for each imaging 
modality. 
 
3.4.4 Quantification of tracer binding 
For the regional quantification of the tracer binding/uptake, we employed regions of interest 
(ROIs) from different brain atlases for each paper, based on the research question and 
hypothesis. 294-299 
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isocortical ROI was created to quantify the Aβ PET data, calculate the cut-offs for Aβ 
positivity, and classify the participants in the ‘Αβ-positive’ and ‘Aβ-negative’ groups. 
 
3.4.4.1 Paper I 
A simplified atlas was used in paper I because of the widespread binding of the Aβ tracers in 
the whole isocortex. Grey-matter ROIs, based on the available MRIs from the DiMI cohort, 
201 were created because of the lack of T1 MRI sequences for all of the DiMI cohort, and 
were later applied to the Aβ PET scans of all study participants (DiMI and ADNI). 
For [11C]PIB and [18F]florbetapir, standardised uptake value ratio (SUVR) images were 
created (over the time intervals 40-60 min and 50-70 min, respectively), and used to quantify 
the tracer binding. A cerebellar grey-matter ROI was used as reference for the [11C]PIB 
images and a whole cerebellar ROI was used for the [18F]florbetapir images. 
 
3.4.4.2 Papers II-V 
Grey-matter was parcellated from T1 MRI sequences using SPM (SPM8, SPM12). Grey-
matter binary masks were created from this parcellation, and these were later applied to 
anatomical atlases for the creation of individual grey-matter ROIs. In papers II-III, in which 
[18F]THK5317 binding was evaluated for the first time in vivo, grey-matter ROIs covering the 
whole brain were applied to all PET tracers. In contrast, for papers IV-V, we selected grey-
matter ROIs predominantly in the temporal cortex, in agreement with the findings of papers 
II-III and the known regional distribution of tau pathology, as described by autopsy studies. 
49,75 
A voxel-wise, reference region-based approach was adopted for the kinetic modelling of the 
dynamic [18F]THK5317 PET imaging data. The Logan graphical method, with reference to 
the cerebellar grey-matter ROI, was applied to the dynamic data over the time interval 30-60 
min to create the distribution volume ratio (DVR) images, a method that has been validated 
against arterial sampling-based quantification of the tracer binding. 227,300 Summation images 
(40-60 min) were used for [11C]PIB and static images (30-45 min) were used for [18F]FDG to 
create SUVR images, with reference to the cerebellar grey-matter and pons, respectively. The 
resulting [18F]THK5317 DVR and [11C]PIB and [18F]FDG SUVR images were sampled with 
the grey-matter ROIs. 
The quantification of the [11C]THK5351, [11C]PBB3 and [11C]AZD2184 dynamic PET 
imaging binding data was modelled using the wavelet-aided parametric imaging method, 301 
which allows the creation of high-resolution, noise-robust, non-displaceable binding potential 
(BPND) images. The cerebellar grey-matter ROI was used as reference for the creation of the 
BPND images, which were subsequently sampled with the grey-matter ROIs. The wavelet-
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aided parametric imaging method was first compared to other kinetic models for validation 
purposes. 226,227,300,302 
 
3.4.5 Partial volume effect correction 
PET is characterised by low spatial resolution and the concentration of a radiotracer might 
therefore be over- or under-estimated in a given ROI due to potential ‘spill-over’ of the signal 
from neighbouring ROIs (aka partial volume effect). Different areas of the brain are 
differentially affected by the partial volume effect; ROIs neighbouring other ROIs that have a 
different target availability or ROIs with significant atrophy are liable to experience greater 
spill-over of the signal. Correction methods can be applied based on detailed structural 
information from the T1 MRI sequence. Specifically, these methods could theoretically 
compensate for the spill-over of the signal by assuming that different tissue classes in the 
brain (e.g. grey- and white-matter) 303 or even individual ROIs, 304 have a homogeneous 
signal. Two T1 MRI-based partial volume effect correction methods were applied to the PET 
data for the purposes of this thesis (papers II, III, V). 
 
3.5 CORTICAL THICKNESS MEASURES 
The thickness of the entorhinal cortex was measured for study V, in the T1 MRI sequence, 
with FreeSurfer image processing software (version 6.0, http://surfer.nmr.mgh.harvard.edu). 
The selection of the entorhinal cortex as a measure of medial temporal atrophy was based on 
previous evidence of a correlation between the binding of another tau-specific PET tracer 
([18F]AV-1451) with underlying atrophy in the same region. 305 
 
3.6 CEREBROSPINAL FLUID BIOMARKERS 
As part of the routine clinical assessment, CSF samples from the patients were analysed at the 
Clinical Neurochemistry Laboratory, Gothenburg University, Mölndal, Sweden. The local 
reference values of <550 pg/mL for Aβ42, >400 pg/mL for total tau, and >80 pg/mL for tau 
phosphorylated at threonine 181 were used to evaluate the presence of AD pathology in the 
patients. 
 
3.7 STATISTICAL ANALYSES 
Diverse statistical analyses (descriptive and inferential) were used in the respective papers 
based on the research question and hypothesis. Detailed descriptions of the different 
approaches used are reported in the respective papers. The approaches to correction for 
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multiple comparisons are also discussed in the individual papers. For the imaging data, 
analyses were performed in a ROI- and voxel-based manner, as discussed below. 
 
3.7.1 Region of interest-based analyses 
The selection of parametric or non-parametric approaches for group comparisons (analysis of 
variance or the non-parametric Kruskal-Wallis analogue for analysis of variance) and 
correlation analyses (Pearson or Spearman rank correlation coefficients) was based on the 
sample sizes and the probability distributions of the selected variables. To investigate the 
relationship between imaging modalities or between an imaging modality and other markers 
of the disease, linear models were constructed for cross-sectional and linear mixed effects 
models for longitudinal data. Mediation analyses were employed to explore the mediation 
effect of a variable in the relationship between a causal variable and an outcome variable. 
Individual annual rates of change in the tracer binding/uptake were calculated, based on the 
longitudinal data. The expectation-maximisation algorithm for Gaussian mixture models was 
employed for clustering groups of individuals based on the probability distribution of specific 
variables. The receiver operating characteristic analysis was used for defining the accuracy of 
Aβ and tau PET imaging in discriminating between cognitively normal volunteers and 
patients with AD, and for selecting optimal cut-off points. For each paper, the ROI-based 
analyses were performed using different versions of the SPSS (Armonk, New York, USA), 
XLSTAT (Addinsoft, New York, USA) or R software (R Foundation for Statistical 
Computing, Vienna, Austria, http://www.R-project.org/). 
 
3.7.2 Voxel-based analyses 
Group comparisons of the tracer binding were performed using standard non-parametric 
procedures based on permutation testing (SnPM13), because of the limited sizes of the 
individual groups. Paired t-tests were employed for investigating changes in the tracer 
binding/uptake over time (SPM8). Correlation analyses were carried out between the local 
binding/uptake results for the different tracers (BPM 3.1). Additional procedures included the 
creation of individual z-score maps for expressing the tracer binding/uptake for an individual 
in relation to a group of cognitively normal volunteers. The same maps were also assessed 
longitudinally for exploring the spread of the tracer binding/uptake in individual patients. 
Maps of the individual annual rates of change were made for the tracer binding/uptake based 
on the longitudinal data. All voxel-based analyses were performed in MATLAB 2012b (The 
MathWorks, Inc., Natick, Massachusetts, USA). 
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4 RESULTS AND REFLECTIONS 
 
More detailed presentation and discussion of the results of each study is included in the 
respective articles/manuscripts. The main findings as well as some methodological 
considerations are described briefly below. 
 
4.1 MAIN FINDINGS 
 
4.1.1 Paper I – Amyloid-β PET imaging 
4.1.1.1 Comparability of [11C]PIB and [18F]florbetapir PET imaging 
The different Aβ PET tracers have shown similar binding properties when injected into the 
same participants, 193-195 although their comparability across different groups was uncertain. 
In our study, it was observed that the binding of [11C]PIB and [18F]florbetapir, when the 
tracers were injected into different individuals from different cohorts (DiMI and ADNI, 
respectively), showed high regional agreement as well as significant correlation across ROIs 
in the different diagnostic groups, which illustrates the similarities between the tracers 
(Figure 14). [11C]PIB showed a higher discriminative ability between cognitively normal 
volunteers and patients with AD than [18F]florbetapir (area under the curve = 0.931 vs 0.864, 
Figure 14. [11C]PIB and [18F]florbetapir SUVR images from age-, gender- and MMSE-matched cognitively 
normal volunteers (CN), patients with MCI (Aβ-negative and -positive) and patients with probable AD. The 
figure is adapted from Chiotis, K. et al. Amyloid PET in European and North American cohorts; and 
exploring age as a limit to clinical use of amyloid imaging. European journal of nuclear medicine and 
molecular imaging 42, 1492-1506, (2015). 
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respectively), a finding that had previously been reported elsewhere, 195 although it was not 
investigated in detail. The wider dynamic range of SUVR values and lower off-target binding 
in white-matter that is observed for [11C]PIB relatively to its [18F] derivatives probably 
contributes to its higher discriminative ability, although it remains unclear if those differences 
could affect the clinical performance of the [18F] Aβ tracers. The differences in discriminative 
ability between the tracers could alternatively be explained by other differences between the 
cohorts. Although we used matched groups of individuals, we cannot exclude that other 
covariates differed. For example, there was a difference in educational attainment between 
cohorts. The participants in the ADNI cohort were, on average, university graduates, whereas 
the average educational attainment of the participants in the DiMI cohort was equivalent to 
high-school graduates. The evidence from the literature suggests differences in the 
distribution of Aβ-positive PET scans depending on the educational attainment of the 
individuals, which could explain the differences in discriminative ability, although this 
phenomenon is not completely understood, especially among patients with AD. 196,306-311 
 
4.1.1.2 Effect of age on the distribution of amyloid-β-positive scans 
The rapid development of Aβ PET imaging led to its approval by the regulatory agencies for 
clinical use in excluding AD pathology in individuals with cognitive impairment. However, 
several questions related to the clinical application of Aβ imaging remain unanswered, 
including the selection of patients (using demographic or clinical information) that would 
benefit the most by the incorporation of this expensive imaging technique in their clinical 
assessment. So far, appropriate use criteria based on the prevalence of different dementia 
syndromes have suggested that Aβ imaging should be used in patients younger than 65 years. 
207 However, little is known on the potential effect of age on the clinical utility of Aβ imaging 
in patients with AD, especially across the wide range of ages affected by this disease. In the 
ADNI participants, we found that Aβ imaging performed better when discriminating between 
cognitively normal volunteers and patients with a clinical diagnosis of AD, who were 
younger (55-75yrs), rather than older (76-93 yrs) (sensitivity = 81 vs 72% and specificity = 
70-80%, respectively). While we would expect a drop in specificity due to the age-related 
accumulation of Aβ in the population, 51 the drop in sensitivity probably reflected the 
substantial number of clinically diagnosed patients with AD in the older subgroup who 
actually did not carry Aβ pathology. A closer look at the distribution of Aβ PET measures 
sheds some light on the uncertain clinical diagnosis of the elderly patients. Specifically, the 
distribution was bimodal in the elderly patients, with a substantial number of individuals 
clearly Aβ-negative (n=15, 22%) (Figure 15). Furthermore, the same patients were less likely 
to be ApoE4 carriers (one out of 15) and, in general, had a pattern of [18F]FDG uptake not 
suggestive of the presence of AD neurodegeneration. Neuropathology studies have pointed in 
the same direction, and our results were verified by a recent meta-analysis of Aβ PET 
imaging data; the prevalence of Aβ positivity decreases with increasing age in patients with a 
clinical diagnosis of AD, which indicates an increased clinical misdiagnosis of AD in the 
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oldest-old in the absence of a reliable pathology marker. 311 Despite its exploratory nature, 
this study offers some insight into the increasing importance of Aβ PET imaging with 
increasing age in the diagnostic assessment of individuals with cognitive impairment. The on-
going large, multi-centre studies (AMYPAD, IDEAS) that intend to evaluate the clinical 
performance of Aβ PET imaging offer a unique opportunity for enhancing our understanding 
of different clinical measures that could define subgroups of patients, where the use of such a 
biomarker would be more advantageous. 
 
4.1.2 Papers II-V – Tau PET imaging in a multi-modal design 
4.1.2.1 Binding of the tau tracer [18F]THK5317 in patients with AD 
The first in vivo evaluation of the tau-specific PET tracer [18F]THK5317 in patients with AD 
(prodromal or dementia) detected high binding of the tracer predominantly in inferior and 
lateral temporal ROIs, regions that have been consistently associated with the presence of tau 
pathology in neuropathological studies of AD (Figure 16). 49,75 In contrast, the cognitively 
 
Figure 15. Frequency density plots of the [18F]florbetapir composite cortical SUVR values in the two age groups 
of cognitively normal volunteers (CN) and patients with probable AD. The dashed line represents the cut-off for 
Aβ positivity with [18F]florbetapir. The figure is adapted from Chiotis, K. et al. Amyloid PET in European and 
North American cohorts; and exploring age as a limit to clinical use of amyloid imaging. European journal of 
nuclear medicine and molecular imaging 42, 1492-1506, (2015). 
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Figure 16. Sample [18F]THK5317 DVR, [11C]PIB SUVR and [18F]FDG SUVR images from an elderly 
cognitively normal (CN) volunteer, a patient with prodromal AD and a patient with AD dementia. Cerebellar 
grey-matter was used as a reference region for [18F]THK5317 and [11C]PIB, and the pons was used for 
[18F]FDG. 
Figure 17. (A, B) Voxel-based group comparisons of [18F]THK5317 binding between cognitively normal 
volunteers and patients with prodromal AD or AD dementia; the voxel-based comparisons were performed in 
SnPM13 and the results are presented after correction for multiple comparisons with the false discovery rate 
method (p<0.05). (C) ROI-based receiver operating characteristic analysis between all cognitively normal 
volunteers and all patients with AD (prodromal and dementia). The area under the curve (AUC) for every cortical 
ROI was reported. The figure is adapted from Chiotis, K. et al. Imaging in-vivo tau pathology in Alzheimer's 
disease with THK5317 PET in a multimodal paradigm. European journal of nuclear medicine and molecular 
imaging 43, 1686-1699, (2016). 
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normal volunteers showed overall low binding of the tracer, with areas of high binding 
limited to the basal ganglia. Statistically significant differences were observed between 
patients with AD and cognitively normal volunteers predominantly in the temporal lobe as 
well as in other isocortical ROIs (Figure 17A, B). Furthermore, the ordering of ROIs with 
regard to discrimination between groups strongly resembled the suggested temporal evolution 
of tau pathology across the AD brain (Figure 17C), 75 in agreement with another study that 
used the same methodology but a different tau tracer (i.e. [18F]AV-1451). 233 The findings of 
this study, together with in vitro evidence highlighting the specificity of this tracer for tau 
deposits, 218 suggest that [18F]THK5317 could image the expected load and regional pattern 
of tau pathology in vivo in a cohort of cognitively normal volunteers and patients with AD. 
Similar findings have been reported in different cohorts, where different tau-specific PET 
tracers were used. 220,312 
The binding pattern of [18F]THK5317 in patients with AD differed from that of the Aβ PET 
tracer [11C]PIB (Figure 16), which further illustrates the differences between the targets of the 
two tracers. However, there were regional correlations between the two markers (Figure 
18A), which may reflect the co-localisation of Aβ and tau deposits during the time course of 
AD, probably in the neuritic plaques. Similar findings have been reported for the tau PET 
tracer [18F]AV1451. 243 Significant correlations between [18F]THK5317 and 
neurodegeneration, as measured by glucose hypometabolism ([18F]FDG), were regionally 
localised in areas vulnerable to neurodegeneration in the fronto-parieto-temporal lobes, 
including the precuneus, highlighting the close link between tau pathology and 
neurodegenerative changes (Figure 18B). 65-68 However, in contrast to other studies published 
with another tracer, the relationship between the tracer binding and the neurodegenerative 
changes was rather focal and did not occur across large cortical areas, 237,240,242 which could 
Figure 18. Voxel-based correlations between (A) [18F]THK5317 (tau) and [11C]PIB (Aβ) binding and (B) 
[18F]THK5317 (tau) binding and [18F]FDG (glucose metabolism) uptake. The correlation analyses were 
performed in BPM 3.1. No correction for multiple comparisons was applied. The figure is adapted from 
Chiotis, K. et al. Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal 
paradigm. European journal of nuclear medicine and molecular imaging 43, 1686-1699, (2016). 
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be attributed to our mildly impaired sample, where only a subset of patients had severe 
hypometabolic changes. 
4.1.2.2 Relationship of tau pathology ([18F]THK5317) with cognitive deficits 
Binding of [18F]THK5317 in patients with AD related negatively to measures of global 
cognition (MMSE, FSIQ) and episodic memory (encoding from the Rey auditory verbal 
learning and delayed recall from the Rey-Osterrieth complex figure tests) (Figure 19). The 
correlations, especially that with episodic memory, were predominantly observed in the 
temporal lobe, where the patients showed increased binding in comparison to a group of 
cognitively normal volunteers. Widespread hypometabolism ([18F]FDG) in fronto-parieto-
temporal areas related positively with measures of global cognition, while the relationship 
with episodic memory was somewhat more restricted spatially in comparison to 
Figure 19. Surface projections describing the relationship of ROI-based tracer binding/uptake ([18F]THK5317 
and [18F]FDG) with global cognitive and episodic memory performance in patients with AD. Linear models 
were employed for investigating relationships with t-values reported for significant associations (p<0.05). No 
correction for multiple comparisons was made. RAVL = Rey auditory verbal learning; ROCF = Rey-Osterrieth 
complex figure. The figure is adapted from Saint-Aubert, L. et al. Regional tau deposition measured by 
[18F]THK5317 positron emission tomography is associated to cognition via glucose metabolism in Alzheimer's 
disease. Alzheimer's research & therapy 8, 38, (2016) 
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[18F]THK5317. From our evidence, tau pathology, relatively to glucose metabolism, seems to 
be more selective for episodic memory changes, while the opposite pattern was observed for 
global cognition. Similar correlations have been observed between the binding of other tau 
tracers and cognition in different patient samples. 231,234,237,313 
Based on current understanding, tau deposition could lead to neuronal dysfunction, neuronal 
death and finally cognitive deficits. 55,69-71 In order to test this hypothesis in vivo, we used 
mediation analyses to investigate possible causal relationships between tau deposition 
([18F]THK5317), glucose metabolism ([18F]FDG) and cognition. Briefly, the prerequisite for 
those analyses was the presence of a statistically significant relationship of the mediator 
variable (glucose metabolism) with the other two variables (tau deposition and cognition). 
This condition was met for [18F]THK5317 and [18F]FDG binding/uptake in the ROIs of the 
temporal lobe and measures of global cognition. A mediating role of [18F]FDG uptake was 
detected in the association of local [18F]THK5317 binding with global cognitive measures. 
Thus, our cross-sectional data support the current hypothesis, according to which increased 
tau deposition leads to cognitive decline by causing local neuronal dysfunction 
(hypometabolism). Our findings are in line with those from another study, which 
incorporated CSF measures instead of PET imaging to trace tau pathology, 314 although the 
strength of our current work is the regional mapping of the pathological changes in the AD 
brain. A study published recently by Bejanin, et al. 315 further validates our observations by 
applying similar models with another tau tracer ([18F]AV-1451). 
 
4.1.2.3 Propagation of tau pathology ([18F]THK5317) in a longitudinal design 
Based on neuropathological evidence, it has been suggested that the regional spreading of tau 
pathology follows the clinical progression of AD in patients; 51,77,78 however, no longitudinal 
tau PET imaging study had been published, which validated these cross-sectional, post-
mortem observations. In our study, we used a longitudinal design to investigate the temporal 
evolution (interval = 17 months) of tau pathology in vivo using PET ([18F]THK5317) in 
relation to changes in glucose metabolism ([18F]FDG) and cognitive performance in a group 
of patients with AD (prodromal or dementia). At a group level, no statistically significant 
increases in [18F]THK5317 binding were observed over time (except for a restricted unilateral 
area in the left inferior temporal gyrus), while [18F]FDG uptake declined significantly in 
widespread temporo-parietal areas (Figures 20, 21). In temporal ROIs, a statistically 
significant negative correlation was observed between baseline [18F]THK5317 binding and 
annual rates of change of [18F]THK5317 binding, which illustrates that the rate of tau 
deposition could even decelerate over time in ROIs with high tau burden at baseline. At an 
individual level, a heterogeneous pattern of increases in [18F]THK5317 binding was 
observed, with differences observed between patients at different clinical stages of AD 
(prodromal or dementia). Binding was increased in more restricted isocortical areas in 
patients with prodromal AD in comparison to patients with AD dementia. This illustrates 
that, although no statistically significant differences were detected at a group level, there were  
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Figure 20. (A) Average baseline and follow-up DVR images from patients with AD 
(prodromal or dementia; n=16) with [18F]THK5317, and (B) voxel-based paired t-tests 
(SPM8) evaluating the changes in binding over time (interval = 17 months). No correction for 
multiple comparisons was made (uncorrected p<0.001). The figure is adapted from Chiotis, 
K. et al. Longitudinal changes of tau PET imaging in relation to hypometabolism in 
prodromal and Alzheimer's disease dementia. Molecular psychiatry, (2017). 
Figure 21. (A) Average baseline and follow-up SUVR images from patients with AD 
(prodromal or dementia; n=16) with [18F]FDG, and (B) voxel-based paired t-tests (SPM8) 
evaluating the changes in uptake over time (interval = 17 months). No correction for multiple 
comparisons was made (uncorrected p<0.001). The figure is adapted from Chiotis, K. et al. 
Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and 
Alzheimer's disease dementia. Molecular psychiatry, (2017). 
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substantial albeit heterogeneous differences at an individual level. Similar heterogeneity was 
also observed, in terms of [18F]THK5317 binding, at baseline in our patient sample. 
Longitudinally, no relationship was observed between [18F]THK5317 binding and [18F]FDG 
uptake in the patients with AD, as assessed by linear mixed-effects models. However, a 
significant interaction was detected between [18F]THK5317 binding and the time points of 
investigations (baseline and follow-up) with regard to the [18F]FDG uptake. Specifically, at 
follow-up the relationship between [18F]THK5317 binding and [18F]FDG uptake was closer 
than at baseline. In other words, although tau pathology and hypometabolism do not seem to 
go hand-in-hand over time, the relationship becomes closer as the disease progresses, i.e. as 
hypometabolism becomes more severe. Cross-sectional in vivo observations with another tau 
tracer ([18F]AV-1451) in samples of patients at different stages of the disease, further 
supported the idea of a closer relationship between tau pathology and neurodegeneration at 
late symptomatic stages of AD (dementia). 240,242,246,316 Altogether, our findings indicate the 
existence of a lag phase between the build-up of tau pathology and the development of 
hypometabolic, neurodegenerative changes. This is in line with some experimental data 
showing that neurons can tolerate a substantial amount of tau pathology, through 
compensatory mechanisms, before exhibiting major degenerative changes. 72-74 
 
4.1.2.4 Binding of the tau tracer [18F]THK5317 in patients with atypical parkinsonism 
A neuropathological diagnosis of CBD and PSP is made in the presence of tau-positive 
deposits, although distinct types and regional distributions of the deposits characterise the two 
diseases (Table 2). 317,318 Both diseases have been associated with clinical symptomatology in 
the spectrum of atypical parkinsonism with broad overlap between their clinical 
presentations. Two patients clinically diagnosed with possible CBD and one with probable 
PSP underwent multi-modal PET imaging as part of our studies (paper II, IV). All three 
patients were negative for Αβ deposition ([11C]PIB PET), they exhibited hypometabolic 
changes ([18F]FDG PET) consistent with the presence of CBD and PSP pathology, 
respectively, and the regional distribution of their [18F]THK5317 binding differed 
substantially from that in patients with AD. [18F]THK5317 binding was higher in the two 
patients with possible CBD than in the cognitively normal volunteers, in areas consistent with 
the expected distribution of tau pathology in this disease; 135 both patients showed increased 
binding in the basal ganglia and cortical areas, while one of the them also showed extensive 
binding in the white-matter (Figure 22). The patient with probable PSP showed high 
[18F]THK5317 binding, predominantly in the basal ganglia and midbrain, in agreement with 
previously published neuropathological studies. 136 Our findings are in line with evidence 
presented using different tau PET tracers, 220,247-252 and illustrate the promise held by the 
existing tracers for differentiating between syndromes associated with different tauopathies. 
The two patients with possible CBD underwent follow-up [18F]THK5317 and [18F]FDG PET 
imaging after intervals of 17 and 24 months. At follow-up, [18F]THK5317 binding in both 
 42 
patients had increased in the basal ganglia as well as other cortical areas, including the frontal 
lobe (Figure 22). Decreases were observed in [18F]FDG uptake over this time. Tau imaging 
with [18F]THK5317 could thus prove more useful in tracking neurodegeneration 
longitudinally in non-AD rather than AD tauopathies, at least in the symptomatic stages of 
these diseases. However, because only two cases of possible CBD were investigated, without 
autopsy validation, we advise caution in the interpretation of our findings. 
  
Figure 22. [18F]THK5317 DVR and [18F]FDG SUVR baseline images as well as annual rate of change maps (Δ 
DVR/SUVR per year) for the binding/uptake of the two tracers in the two patients with clinical diagnosis of 
possible CBD. The figure is adapted from Chiotis, K. et al. Longitudinal changes of tau PET imaging in relation 
to hypometabolism in prodromal and Alzheimer's disease dementia. Molecular psychiatry, (2017). 
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4.1.2.5 Differences between tau-specific tracers; relationship to other markers of AD 
Similar findings have been presented in vivo when chemically different tau PET tracers were 
administered to different patients with AD or non-AD tauopathies, as discussed above. 223 
However, head-to-head comparisons of those tracers in the same individuals were lacking. In 
our study, the tau tracers [11C]THK5351 (successor of THK5317) and [11C]PBB3 were 
injected on the same day into the same patients, who were diagnosed with clinical AD 
(prodromal or dementia), to compare their binding properties. [11C]THK5351 bound with a 
higher load in the brains of the patients, than [11C]PBB3, with both tracers exhibiting high 
binding in the temporal lobe, as well as other isocortical ROIs (Figure 23). However, the 
regional distribution of [11C]THK5351 and [11C]PBB3 binding differed substantially, 
especially within the temporal lobe. More specifically, while [11C]THK5351 showed the 
highest binding in the medial relative to the lateral temporal lobe, the opposite pattern was 
detected for [11C]PBB3. The binding of [11C]PBB3, but not of [11C]THK5351, resembled that 
of the Αβ tracer [11C]AZD2184 in the temporal lobe and strong positive correlations were 
observed between the binding of [11C]PBB3 and [11C]AZD2184. Measures of tau in the CSF, 
and downstream markers of AD such as entorhinal cortex atrophy and global cognitive 
performance were more closely related to the binding of [11C]THK5351, than to that of 
[11C]PBB3. The differences in the load and regional distribution of the binding suggest 
different molecular targets for the two tau PET tracers. The correlations of the [11C]PBB3 
binding with the binding of the Aβ tracer, suggest that [11C]PBB3 could bind preferentially to 
tau deposits co-localised with Aβ pathology (i.e. neuritic plaques). 319,320 In contrast, the 
Figure 23. Average [11C]THK5351 (tau), [11C]PBB3 (tau) and [11C]AZD2184 (Aβ) BPND images for the patients 
with AD (prodromal or dementia; n = 9). BS = brainstem; CP = choroid plexus; DVS = dural venous sinus; FL 
= frontal lobe; LTL = lateral temporal lobe; MTL = medial temporal lobe; PQ = precuneus; PL = parietal 
lobe; PUT = putamen; THA = thalamus. 
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pattern of [11C]THK5351 binding matched the expected spatial distribution of tau pathology 
in AD better, suggesting binding of the tracer to a wider range of tau deposits. 75,321 
 
4.2 METHODOLOGICAL CONSIDERATIONS 
 
4.2.1 Tau PET imaging 
4.2.1.1 Test-retest evaluation 
Test-retest studies are crucial in the in vivo evaluation of the utility of novel tracers. 
[18F]THK5317, when injected into the same patients within an interval of 37 days, showed 
excellent reproducibility, especially in regions of particular interest for tau pathology. In the 
temporal cortex, the average absolute difference in [18F]THK5317 binding between test and 
retest was 1.83% (standard deviation = 1.00%). Low variability was also observed in ROIs 
considered affected by ‘off-target’ binding of the tracer, as discussed below. As an example, 
the average absolute difference in [18F]THK5317 binding in the putamen between test and 
retest was 1.51% (standard deviation = 1.07%). 
 
4.2.1.2 Off-target binding 
The binding of [18F]THK5317 and its successor 
[11C]THK5351 was extensive in areas that are not 
expected to be affected significantly by tau pathology 
(likely, off-target binding) in cognitively normal 
volunteers or patients with early AD, 49 such as the basal 
ganglia, thalami and brainstem (Figures 23, 24). Binding 
in the basal ganglia appeared to be of higher intensity in 
the elderly compared with younger, cognitively normal 
volunteers, although there was very good discrimination 
in the same area between groups of cognitively normal 
volunteers and patients with AD (prodromal or 
dementia) or atypical parkinsonism. Off-target binding 
in the basal ganglia and thalami has been associated with 
binding of the tracer to monoamine oxidase B (MAO-
B). 236 Although, the discrimination between patients 
with atypical parkinsonism and cognitively normal 
volunteers could indicate a tau component in the binding 
in those areas, the source of increased binding in patients 
with AD remains unexplored. Interestingly, the 
structurally different tau tracer [11C]PBB3 was also 
Figure 24. Sample [18F]THK5317 DVR 
images illustrating the off-target binding 
of the tracer in areas such as the basal 
ganglia, thalamus and brainstem from a 
young cognitively normal (CN) volunteer 
(22 yrs), an elderly CN (58 yrs) and a 
patient with AD of the same age (58 yrs). 
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bound extensively to the MAO-B-rich basal ganglia in patients with AD, although the 
comparability of off-target binding sources between tracers remains elusive. Additional areas 
of off-target binding for [11C]PBB3 were detected in vascular structures, including the 
choroid plexus and the dural venous sinuses (Figure 23). 
 
4.2.1.3 Partial volume effect correction 
The extensive off-target binding of the investigated tau tracers could potentially lead to spill-
over of the signal to the adjacent ROIs, especially when conventional PET scanners with low 
spatial resolution (e.g. ECAT EXACT HR+ scanner and Discovery ST PET/CT) are used. 
We used different methods to correct for this partial volume effect. In the uncorrected 
[18F]THK5317 DVR images no differences were observed in the hippocampus between the 
cognitively normal volunteers and patients with AD, possibly because of off-target tracer 
binding in the basal ganglia, which led to spill-over of signal. Application of partial volume 
effect correction accounted for the spill-over and revealed that the groups could be 
differentiated moderately well based on the load of tracer binding (Figure 25). A similar 
effect was observed in the anterior cingulate. For [11C]THK5351 and [11C]PBB3, the partial 
volume effect correction did not substantially affect the quantification of the tracer binding, 
probably because of the high-resolution of the PET system (HHRT), which minimised the 
spill-over between ROIs. However, it is appears that the use of these tracers in conventional 
scanners would result in substantial spill-over of the signal and therefore bias in the regional 
quantification of the tracer binding. 
 
Figure 25. Boxplots of [18F]THK5317 binding in the hippocampus before and after the application of partial 
volume effect correction across diagnostic groups. CN = cognitively normal volunteers. The figure is adapted 
from Chiotis, K. et al. Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a 
multimodal paradigm. European journal of nuclear medicine and molecular imaging 43, 1686-1699, (2016). 
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5 CONCLUDING REMARKS 
 
• The developed Aβ-specific PET tracers, [11C]PIB and [18F]florbetapir, were highly 
comparable even when applied to different cohorts. The oldest old patients with 
cognitive complaints might benefit substantially from the use of Aβ PET as part of 
their clinical assessment. 
 
• The tracer [18F]THK5317 detected the expected load and regional distribution of tau 
pathology in vivo in a sample of patients with clinical AD (prodromal or dementia) 
and patients with atypical parkinsonism. The distribution of [18F]THK5317 binding 
differed from that of Aβ deposition ([11C]PIB) in AD, although there were regional 
correlations. 
 
• The regional load of tau pathology ([18F]THK5317) is associated with measures of 
global cognition and episodic memory. Local hypometabolism ([18F]FDG) appeared 
to play a mediating role in this relationship. 
 
• Heterogeneous patterns of change over time were observed in the binding of the tau 
tracer [18F]THK5317 in patients with AD, in contrast to homogeneous changes in 
glucose metabolism ([18F]FDG), which tracked cognitive deterioration better. The 
build-up of tau pathology and the development of local hypometabolism appeared 
temporally dissociated, at early symptomatic stages of AD, with a stronger 
relationship detected when hypometabolism changes become more prevalent in the 
later stages. 
 
• The tau tracers [11C]THK5351 and [11C]PBB3 seem to bind to different molecular 
targets in vivo. Binding of [11C]PBB3 appeared to be more closely related to Aβ 
deposition ([11C]AZD2184), while [11C]THK5351 binding followed the expected 
regional pattern of tau pathology in AD more closely and was more closely related to 
downstream markers of the disease. 
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6 FURTHER CONSIDERATIONS 
 
Although the results of tau PET imaging are promising, a number of concerns have also been 
raised, predominantly related to the lack of thorough characterisation of the binding targets 
for each tracer, as discussed below. Therefore, caution is advised in interpreting the in vivo 
findings published to date. Future research should focus on validating the binding of the 
existing PET tracers as well as on developing new tracers with improved pharmacological 
properties, based on the lessons learned from the evaluation of the first generation of tracers. 
 
6.1 SPECIFIC TARGETS OF TAU PET TRACERS 
The specific targets of the developed tau PET tracers remain uncertain. Although all tracers 
have shown high specificity to tau pathology in in vitro studies, 223 the heterogeneity of tau 
deposits complicates the identification of their specific targets, in the absence of detailed 
validation studies. Furthermore, the differences in chemical structure of the existing tracers 
raise doubts about the comparability of their binding properties on the tau deposits. To date, 
studies directly comparing the in vitro binding of the tracers have highlighted differences in 
their binding characteristics. The tracers in the THK family (THK5317, THK5351) and AV-
1451 appear to have similar binding properties in the AD brain while PBB3 has different 
properties, as illustrated by competition studies. 224,225 These observations have been 
reinforced by in vivo comparisons in the same patients with different tracers, both in paper V 
and the work of Jang, et al. 322. Therefore, although we know very little about the specific 
targets of these tracers, we now understand that at least one of them (PBB3) binds to different 
molecular sites from the rather similar targets that THK5317, THK5351 and AV-1451 bind 
to. The identification of tracers binding to different aspects of tau pathology may have 
important implications for the differentiation of tauopathies, as well as for exploration of the 
temporal evolution of tau pathology in the diseased brain. 
The determination of the 3D molecular structure of paired helical and straight tau filaments 
323 could offer new insight into the development of future tau PET tracers. The use of 
computational simulation studies (in silico modelling) will allow detailed investigation of the 
tracer binding sites on the tau fibril in greater detail, as well as allow determination of 
whether the tracers preferentially bind to different types of tau filaments. In addition, more 
detailed characterisation of the tracer binding is expected with the post-mortem validation of 
tracer binding in end-of-life patients. These studies will reveal whether the tracers bind to 
different types of tau deposits or even to different maturation stages of these deposits. The 
elucidation of the binding characteristics is crucial for interpreting in vivo PET observations 
in both AD and non-AD tauopathies. 
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6.2 OFF-TARGET BINDING OF TAU PET TRACERS 
The in vivo binding of the developed tracers to areas not expected to be affected by tau 
pathology, both in cognitively normal volunteers and patient groups was somehow largely 
neglected in the first in vivo studies, 219,220,231,324 probably as a result of the commercial 
interests surrounding the development of many of the tau-specific tracers. Briefly, recent 
studies have suggested off-target binding for the tracers to misfolded proteins other than tau 
(e.g. TDP-43, α-synuclein, Aβ), enzymes (e.g. MAO-A, MAO-B), and vascular structures. 
 
6.2.1.1 Misfolded proteins 
The preliminary evidence pointing to binding of tau tracers to misfolded proteins other than 
tau 257,258,325-328 has led to the ‘tau-specificity’ of these tracers being questioned. So far, PBB3 
appears to have affinity for α-synuclein, the tracers of the THK family and AV-1451 show 
high binding in vivo in syndromes associated with TDP-43 pathology, and the THK tracer 
family could have some affinity for Aβ deposits, according to in vitro work. While the latter 
observations remain to be validated in ante-/post-mortem studies, concerns have been raised 
that these tracers might bind in vivo to multiple β-sheet structures (‘amyloids’), although with 
a different affinity from that to tau pathology. If this proves to be the case, the clinical utility 
of the developed tracers would be undermined, since the discrimination between different 
neurodegenerative diseases characterised by the accumulation of misfolded proteins (aka 
proteinopathies) would be at least questionable. 
 
6.2.1.2 Monoamine oxidase B 
Extensive binding in the basal ganglia has been reported in vivo for AV-1451 and tracers of 
the THK family, in both cognitively normal volunteers and patients with AD. 250,329 However, 
the basal ganglia are minimally affected by tau pathology in both normal ageing and the early 
stages of AD. 49 The binding of the THK tracers to the basal ganglia has been attributed to 
off-target binding to MAO-B, 236 a finding that is consistent with the regional distribution of 
MAO-B in the brain. 330 However, a study that attempted to block the MAO-B signal in vivo 
by administering a MAO-B inhibitor prior to the THK5351 PET scan detected decreases in 
the signal compared to a baseline THK5351 investigation, irrespective of the cerebral 
distribution of MAO-B. Surprisingly, when the binding was quantified using a conventional 
reference region-based approach, no differences were noted in terms of binding before and 
after the administration of the inhibitor. This apparent discrepancy could derive from changes 
in the perfusion of the tracer following administration of a MAO-B inhibitor. In other words, 
the MAO-B inhibitor could lead to decreased delivery of the tracer across the whole brain, 
possibly through nitric oxide-mediated vasodilation, 331 which could mask small differences 
in the binding of THK5351 before and after administration of the inhibitor. Given the very 
strong correlation between AV-1451 and tracers of the THK family in the basal ganglia when 
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injected in the same patients, 322 it is conceivable that the source of off-target binding is – at 
least partly – similar for these tracers. Interestingly, as illustrated in paper V, PBB3 also binds 
in vivo to the MAO-B-rich basal ganglia. Altogether, the potential binding of chemically 
different tau tracers to the same off-target site might indicate the existence of similarities 
between binding sites on tau pathology and MAO-B. Detailed validation studies are required 
to determine the contribution of MAO-B in the in vivo signal of the developed tau tracers and 
to define the brain areas that are affected the most. Potential binding of the tracers to MAO-B 
has increased relevance in non-AD tauopathies, such as CBD and PSP, where ROIs with high 
MAO-B availability and tau pathology overlap (e.g. basal ganglia).  
 
6.2.1.3 Vascular structures 
AV-1451 and PBB3 both bind to vascular structures, which could complicate the 
quantification of the tracer binding in multiple ROIs. The source of this binding for AV-1451 
has so far been attributed to multiple causes, 217,259,332 with no studies investigating further 
this issue for PBB3. 
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7 FUTURE OUTLOOK 
 
The use of tau PET imaging for ever larger cohorts of patients with AD and non-AD 
tauopathies, and for cognitively normal elderly, could offer valuable insight on the temporal 
evolution of tau pathology in the diseased brain, as well as offering a useful tool for the 
differential diagnosis of different proteinopathies. 
 
7.1 TEMPORAL EVOLUTION OF TAU PATHOLOGY 
Tau PET in vivo studies with [18F]THK5317, [18F]THK5351 and [18F]AV-1451 have 
indicated that lateral temporal cortical areas are already affected by tau deposition in the 
earliest symptomatic stages of AD (prodromal AD). 237,312,329 This suggests that tau 
propagates outside the medial temporal lobe already in the preclinical, presymptomatic 
phases of the disease, in agreement with previous models based on neuropathological data. 
51,83 Data from several studies have suggested that tau deposition in the temporal lobe is 
related to markers of neurodegeneration and early cognitive deficit (i.e. episodic memory 
impairment), 237,246,315,329,333 with this relationships becoming stronger when 
neurodegenerative changes become more prevalent. 334 Based on these observations, it is 
conceivable that there is a lag phase between the build-up of tau pathology and the 
development of neurodegeneration, where the deposition of tau precedes the changes in 
markers of neurodegeneration and cognitive impairment. Although it is difficult to infer the 
temporal relationship between Aβ and tau depositions based on the current observations, the 
existence of Aβ-positive, cognitively normal volunteers with relatively low levels of tau in 
the lateral temporal lobe indicates that the spreading of tau pathology outside the medial 
temporal areas follows in time the cortical accumulation of fibrillar Aβ. 231 Overall, we 
suggest that tau pathology spreads early in the lateral areas of the temporal cortex before the 
onset of neurodegenerative changes and cognitive deficits, but after the cortical accumulation 
of Aβ plaques (Figure 26). Based on earlier evidence for other biomarkers, 286 we 
hypothesised a sigmoid-shaped curve for depicting the temporal course of tau pathology. 
Furthermore, it is likely, based on neuropathology data and early in vivo evidence, 49,233,234 
that the proposed time course could be shift leftward or rightward on the time axis to better 
depict the earlier deposition of tau in the medial temporal lobe or the later spread in 
isocortical areas outside the temporal lobe, respectively. Future studies adopting a multi-
modal design across the whole spectrum of the disease will improve our understanding of the 
temporal evolution of tau in the AD brain and offer a chance to validate the proposed model. 
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7.2 CLINICAL UTILITY OF TAU PET IMAGING 
The tau PET tracers have shown promising results at detecting the underlying load of tau 
pathology in clinically diagnosed AD and non-AD tauopathies that could lead to future 
breakthrough in the field of tauopathies. 220,230-232,246-252,329,334 Further research should 
concentrate on determining whether the different tau PET tracers can discriminate between 
patients diagnosed with AD or non-AD tauopathies as well as other non-tau-related 
proteinopathies, based on the load and regional distribution of the tracer binding. This 
differentiation could lead to great advances in the early, accurate clinical diagnosis, especially 
in the field of non-AD tauopathies, such as CBD and PSP, where there is, to date, a lack of 
reliable pathology markers able to be used in the clinic. 
Figure 26. (A) Proposed model of the temporal ordering of the different pathological changes during the 
development of AD based on biomarker findings for astrocytosis, Aβ and tau deposition, neurodegeneration 
and cognitive impairment. (B) Temporal shift of the time course of the build-up of tau deposition for different 
brain ROIs. ISOCX = isocortex; MTL = medial temporal lobe; LTL = lateral temporal lobe. 
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